Superparamagnetic iron oxide nanoparticles for early detection of calcific aortic valve disease by Meisel, Cari
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2019
Superparamagnetic iron oxide
nanoparticles for early detection of


















SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES FOR EARLY  
 










CARI LYNN MEISEL 
 
B.S.E., University of Pennsylvania, 2011 








Submitted in partial fulfillment of the 
 
requirements for the degree of 
 














































© 2019 by Cari Meisel All rights reserved except for chapter 2 and Figure 4.5, 








First Reader   
 Joyce Y. Wong, Ph.D. 
 Professor of Biomedical Engineering 





Second Reader   
 Allison Dennis, Ph.D. 
 Assistant Professor of Biomedical Engineering 





Third Reader   
 Tyrone M. Porter, Ph.D. 
 Associate Professor of Mechanical Engineering 
 Associate Professor of Materials Science and Engineering 





Fourth Reader   
 Dimitrios Mitsouras, Ph.D. 
 Assistant Professor of Radiology 
 Brigham and Women’s Hospital 





Fifth Reader   
 Frederick Schoen, M.D., Ph.D. 
 Professor of Pathology and Health Sciences and Technology 
 Brigham and Women’s Hospital 




This work has been supported by a Biomolecular Pharmacology Training grant 
from the NIH/NIGMS (5T32HL007969-13), a training grant from the NIH in 
Inflammatory Disorders (5T32AI089673-05), and a training grant from the NIH in 
Cardiovascular Biology (5T32GM008541-17). This work was performed in part at 
the Center for Nanoscale Systems (CNS), a member of the National 
Nanotechnology Coordinated Infrastructure Network (NNCI), which is supported 
by the National Science Foundation under NSF award no. 1541959. CNS is part 
of Harvard University.  
I would like to acknowledge contributions to this research from several lab 
members, mentors, collaborators, and undergraduates throughout the years.  
So many undergraduates have done work with me and/or on various SPION-
related projects since I started in the lab: Shivem Shah, Olivia Hale, Jordan Nustad, 
Nikita Patil, and Polly Bainbridge. Thank you so much for your time and hard work! 
And thank you to the Undergraduate Research Opportunities Program (UROP) at 
Boston University for their support. 
To Joyce: thank you for being my advisor for the last 5 years. I have so much 
appreciated your insight, encouragement, and mentorship. Thank you for looking 
over my results and helping me make sense of them, for always knowing the right 
person to ask when I have a random question, and for asking me the challenging 
questions necessary to push me in the right direction. None of this would have 
 
v 
been possible without your help and guidance. 
To my committee: thank you so much for all of your input and insight over the years. 
It has been an absolute pleasure to work with all of you, and help and feedback on 
my work have been invaluable. 
To Jo Ann: thank you for being our Lab Mom. Thanks for sitting next to me, sharing 
recipes, and for all of your advice and help over the years. Thank you for 
proofreading everything I’ve written, and for your insightful feedback on every 
presentation I’ve given. I could not have done this without your help.  
To all the folks who have been in the Wong lab while I’ve been around: my time 
here would not have been nearly as fun without all of you. Thanks for bringing food 
to lab meetings, going on long lunch breaks, and not judging me when I’ve taken 
naps at/under my desk. Thank you also for letting me bounce countless ideas off 
of you and show you graphs and figures and ask you “Does that make sense?” 
approximately one million times. 
And to my family and friends: thank you for keeping me (mostly) sane while I’ve 
been doing this thing. Thanks for letting me talk to or at you about my research ad 
nauseum, for letting me practice presentations, for asking me to explain how MRIs 




SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES FOR EARLY 
DETECTION OF CALCIFIC AORTIC VALVE DISEASE 
CARI LYNN MEISEL 
Boston University College of Engineering, 2019 
Major Professor: Joyce Y. Wong, Ph.D., Professor of Biomedical Engineering, 
Professor of Materials Science and Engineering 
ABSTRACT 
 
Calcific Aortic Valve Disease (CAVD) is the most common acquired valvular 
disorder in developed countries, and is estimated to affect more than 5 million 
Americans. In its severe form, the disease results in hemodynamically significant 
aortic stenosis, which causes a variety of negative physiological impacts to 
patients. All told, the physiological consequences of the disease mean that the 
heart must work harder to pump blood throughout the body, causing the heart 
muscle to weaken and putting patients at a significantly greater risk of 
cardiovascular event. However, no clinical imaging method currently available has 
the ability to reliably detect early CAVD, necessarily delaying diagnosis until 
patients are symptomatic and the disease has progressed to its late stages. 
Despite the extensive cost, recovery time, and heightened risk of post-surgical 
complications to patients, surgical approaches are often the only option for patients 
with aortic stenosis due to late diagnosis of the condition. The lack of diagnostic 
imaging techniques capable of detecting and monitoring early-stage disease is a 
major unmet need in the development of new treatments of CAVD. 
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To address this problem, we have developed a novel contrast agent for MRI to aid 
in earlier detection of CAVD by using chemically modified and targeted 
superparamagnetic iron oxide nanoparticles (SPIONs) targeted to hydroxyapatite 
(HA). We have characterized the in vitro physiochemical and binding properties of 
these SPIONs as well as the selectivity of their targeted binding. We have also 
done work to optimize the binding and MRI contrast properties of the SPIONs. 
Finally, we have assessed the medically-relevant properties of the SPIONs, 
including their potential for toxicity and systemic effects and their binding to excised 
human aortic valve samples.  
Our results show that these HA-targeted SPIONs can be successfully fabricated 
via a fairly simple reaction scheme, and that they bind selectively to HA even in 
the presence of serum proteins. We have also determined that the reaction 
scheme for the addition of the poly(ethylene glycol) (PEG) is of particular 
importance in optimizing the MRI contrast properties of the SPIONs. Having a 
hydrophilic group linking the PEG to the SPIONs yields particles with the highest 
contrast. Additional studies indicated that these SPIONs do not have cytotoxic 
properties, and that they are not expected to interfere systemically with bone 
homeostasis, as they neither inhibit nor encourage HA nucleation and formation. 
We have confirmed that these particles are able to cross an endothelial barrier, 
and to bind to HA subsequently. Finally, we have demonstrated targeted binding 
of SPIONs to sites of calcification in excised human aortic valve tissue. All together, 
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these studies indicate that these HA-targeted SPIONs are suitable for further 
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Chapter 1: Introduction and Specific Aims 
1.1  Motivation: Calcific Aortic Valve Disease and Aortic Stenosis 
Calcific Aortic Valve Disease (CAVD) is a general term for any disease that 
involves calcification of the aortic valve, which serves to control blood flow from 
the left ventricle of the heart to the aorta and the rest of the body (Figure 1.1).1,2 
CAVD is the most common acquired valvular disorder in developed countries, and 
is estimated to affect more than 5 million Americans.3  
 
Figure 1.1: Illustration of the location of the aortic valve in the heart, as well as the 
difference between a normal valve and a stenotic valve in the open and closed states. The 
stenosis both prevents the valve from fully closing and hinders valve opening.   
 
While the specific etiology of the disease is largely unknown, it is understood that 






calcification, 30–40% of cases are associated with calcification of a congenital 
bicuspid valve, and fewer than 10% of cases can be traced to acute rheumatic 
fever post-inflammation.4 Regardless of the cause, the physiological impact on 
patients presenting with the disease can be severe.   
In its early stages (aortic valvular sclerosis), CAVD is characterized by valve 
thickening due to lipocalcified deposits without left ventricular outflow obstruction.5 
Up to 25-30% of those over 65 years of age have aortic sclerosis, which is 
associated with a 50% increase in risk of a cardiovascular event.6 As sclerosis 
progresses, the reduction in size of the valve orifice eventually results in 
hemodynamically significant stenosis, referred to as aortic stenosis (AS).5 The 
difference between a normal valve and a stenotic valve is illustrated in Figure 
1.1.1,2 AS results in significant negative physiological impacts to patients, including 
increased ventricular wall stress, decreased stroke volume, and increased end-
systolic volume.4 All told, the physiological consequences of the disease mean that 
the heart must work harder to pump blood throughout the body, causing the heart 
muscle to weaken and putting patients at a significantly greater risk of 
cardiovascular event.4 Given its prevalence and the aging of the national and 
global population, CAVD poses a significant socio-economic burden that current 





1.2 Current Clinical Practices in Aortic Stenosis 
AS is typically first observed during routine examination of the heart and circulatory 
system, where certain characteristics of the peripheral pulse or heartbeat can be 
indicative of the condition.7 Symptomatic patients may additionally present with 
shortness of breath, syncope, and chest pain.5 Confirmation of the diagnosis relies 
on one of the three primary methods of medical imaging used in the clinic today: 
ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI).  
An echocardiogram (heart ultrasound), the current reference standard for CAVD 
diagnosis and follow-up, detects leaflet thickening and late changes in 
transvalvular flow, regurgitation or leakage volume, and pressure differential due 
to aortic valve area reduction.8,9  This can confirm the diagnosis by providing 
information about the physiological parameters as summarized in Table 1.1,4 thus 
helping to stage the disease as well. In late stages of the disease, Computed 
Tomography (CT) can readily assess calcium burden, which may also have 
prognostic value, but cannot assess valve hemodynamics and has limited ability 
to detect and quantify calcium in early lesions.10,11 Cardiac magnetic resonance 
imaging (MRI), although less available, provides similar hemodynamic information 
to echocardiography in addition to assessing myocardial viability, which can have 
important prognostic value.9 Treatment practices and recommendations for 
patients with aortic valve stenosis vary depending on the disease progression and 








Aortic Valve Area 
(cm2) 
Mild 2.0 – 2.9 < 20 1.5 – 2.0 
Moderate 3.0 – 3.9 20 – 39 1.0 – 1.5 
Severe 4.0 – 4.9 40 – 59 0.6 – 1.0 
 
Table 1.1: Summary of diagnosed aortic stenosis severity based on measured patient 
parameters.  
The recommended clinical practice in mild cases, where the patient may be 
asymptomatic or mildly symptomatic, is to monitor any changes in condition 
without further treatment.13 Patients with mild, asymptomatic aortic stenosis show 
high rates of event-free survival one year after diagnosis (92 ± 5%).14 However the 
risk of cardiovascular event and/or death increases with each year subsequent to 
diagnosis, and event-free survival decreases to 60 ± 4% after just 5 years.13 The 
monitoring approach used in mild cases is necessary by default, as there are 
currently no widely-accepted lifestyle or pharmacological interventions for early-
stage CAVD.15 Although the effect of lipid lowering via statins has been studied, 
there is no data to suggest that such measures are effective in preventing or 
slowing the development of AS.16  
The preferred treatment for patients with moderate to severe AS (symptomatic or 
asymptomatic) is valve repair or replacement, without which up to 50% of patients 
would not survive more than 2 years.4,17 This replacement may be surgical 
(surgical aortic valve replacement – SAVR) or, in selected patients, minimally 
invasive (transcatheter aortic valve replacement – TAVR).18 TAVR was approved 
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by the FDA in 2012 as a non-invasive option for high-risk patients, and is currently 
under examination for lower risk patients in several clinical trials.19,20 Each year, 
approximately 75,000 SAVR procedures are performed in the United States, while 
in 2015, 24,808 TAVR procedures were performed.19,21 The overall number of 
aortic valve replacements is projected to increase in the future as the population 
continues to age.  
Although both SAVR and TAVR are effective treatments, both methods remain 
costly; studies report that each of the >100,000 valve replacements performed in 
the US per year22 have associated costs of $27K-43K per “quality-adjusted life 
year” (QALY) for SAVR, and $55-$62K per QALY for TAVR.23 Valve replacement 
surgery also significantly impacts patients’ lives, with recovery times up to 10-12 
weeks for high activity work.4 In addition, patients may experience adverse post-
surgical events such as stroke, atrial fibrillation, or valve 
deterioration/restenosis.24,25 
Despite the extensive cost, recovery time, and heightened risk of post-surgical 
complications to patients, surgical approaches are often the only option for patients 
with aortic stenosis due to late diagnosis of the condition. Ultimately, no clinical 
imaging method currently available has the ability to reliably detect early CAVD, 
necessarily delaying diagnosis until patients are symptomatic and the disease has 
progressed to its late stages.4,17,26–29 The lack of diagnostic imaging techniques 
capable of detecting and monitoring early-stage disease is a major unmet need in 
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the development of new treatments of CAVD. 
 
1.3 Characteristics of Early Stage CAVD  
Earlier diagnosis of CAVD would necessarily rely on early disease markers and 
characteristics. Fortunately, early CAVD progression continues to be a heavily 
researched topic, with a wide body of published literature available.  
Current thinking postulates that the disease is initiated by endothelial disruption 
due to increased mechanical or decreased shear stress on the aortic valve. 
Although the cause of these changes in stress may not be known, hypertension is 
thought to play a role based on clinical research in humans.30,31 It has been 
hypothesized that hypertension may result in high tensile stress on the leaflets of 
the aortic valve, or, alternately, that high volume flow rates such as those observed 
in patients with hypertension may cause turbulent blood flow patterns and low 
shear stress.32,33 In either of these scenarios, endothelial disruption or injury would 
result.  
As with atherosclerosis, this endothelial disruption is followed by inflammation, 
collagen and extracellular matrix disruption, lipoprotein deposition, and formation 
of microscopic calcification sites.5,34–37 Although much of this research has been 
performed on samples from human aortic valves, some of it has been performed 
using mouse models similar to those used for atherosclerotic research, and thus 
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results may not necessarily translate directly to the disease path in human aortic 
valve disease. Photomicrographs depicting these changes to can be seen in 








Figure 1.2:  (A) Apolipoprotein B is observed in morphologically early human aortic valve 
lesions but not in normal valve regions through low-power photomicrograph stained via 
immunoreaction, (B) Apolipoprotein a is observed in morphologically early human aortic 
valve lesions but not in normal valve regions through low-power photomicrograph stained 
via immunoreaction, (C) Aortic valve leaflets of wild-type mice are thin with no macrophage 
infiltration, while leaflets of 30-week-old, hypercholesterolemic apolipoprotein E–deficient 
mice have an increased overall thickness associated with macrophage accumulation (D) 
Density dependent color SEM micrographs of human aortic valve presenting 
microcalcifications. 
 
As the disease progresses, active calcification and lesion formation are observed; 
this may be in part due to the transdifferentiation of cardiovascular cells into 
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osteoblast-like cells.5,34–36 These stages of the disease precede the typically 
diagnosable markers previously discussed such as decrease in aortic valve area 
and increase in aortic jet velocity.5,34–36 Although early CAVD remains an active 
field of research, there has been little to no impact of this research on clinical 
treatment or diagnosis of CAVD and AS at this time. 
1.4 Medical Imaging and Contrast Agents 
The growing and detailed understanding of early-stage CAVD admits the 
possibility of earlier diagnosis via ultrasound, CT, or MRI. MRI has distinct 
advantages over both ultrasound imaging and CT scans for potential applications 
in early CAVD detection. Ultrasound imaging of heart structures 
(echocardiography) suffers from interference from nearby bone or air, and results 
are often very operator-dependent, while CT scans carry a high dose of ionizing 
radiation which may become dangerous for the patient upon repeated exposure 
and scanning.8–10 MRI is advantageous because it can provide more information 
about blood flow, more accurate tissue characterization, and often, better image 
contrast than other imaging modalities.8 However, as discussed previously, MRI is 
not currently sensitive enough to detect early signs of CAVD, including valve 
thickening and the presence of microcalcifications. The use of a contrast agent 
would increase MRI sensitivity, and make it possible to use this imaging modality 
for early CAVD detection.  
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MRI contrast agents function by altering either longitudinal (T1) or transverse (T2) 
relaxation times of protons in proximity to the contrast agents (Figure 1.3).38–42 To 
the viewer, this results in a change in the grey-scale image produced by the scan 
that can serve to highlight or darken desired features.  
 
 
Figure 1.3: Illustration of the impact (A) longitudinal (T1) and (B) transverse (T2) MRI 
contrast agents. Contrast agents act to shorted T1 or T2 (blue line) in comparison to a scan 
without contrast (red line). MRI images with (C) longitudinal (gadolinium-based) and (D) 
transverse (iron-oxide based) contrast agents applied. Panels on the left are scans taken 
prior to the administration of contrast; panels on the right are scans taken after contrast 
agent administration.40–42  
The two most commonly researched MRI contrast agents currently are gadolinium-
based agents and iron-oxide-based agents. Gadolinium-based agents 
preferentially shorten T1 relaxation rates at low doses (Figure 1.3C), and so yield 
“bright spots” in areas of accumulation in T1-weighted images.43 However, 
gadolinium-based agents have been shown to carry potential safety risks, 
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including nephrotoxicity and neurotoxicity.44–47 Superparamagnetic iron oxide 
nanoparticles (SPIONs) are iron-oxide-based MRI contrast agents that function by 
reducing the T2 signal of nearby tissue, leading to a darkened area in T2-weighted 
MRI images (Figure 1.3D).38,48 Several SPION-based MRI contrast agents have 
been approved by the FDA for clinical use for various indications, and they 
continue to be an active area of research.49,50 SPIONs have the further advantage 
of not presenting the same associated safety risks as gadolinium-based contrast 
agents.45 However, hypersensitivity or anaphylaxis reactions have been reported 
in the FDA-approved, carbohydrate-coated iron oxide agent Feraheme,51 
indicating that further clinical evaluation of any potential iron-oxide based contrast 
agent would be of the utmost importance. Literature demonstrates that SPIONs 
can be surface-functionalized using fairly basic chemistry techniques, allowing 
them to be targeted toward specific cells or cell characteristics.52–55 This opens up 
a wide variety of applications, including specific disease detection.  
 
1.5 Research Objective Statement  
The stated goal of this dissertation is to develop and characterize a novel contrast 
agent for MRI to aid in earlier detection of CAVD by using chemically modified and 
targeted SPIONs (see Figure 1.4). Earlier CAVD diagnosis and improved 
monitoring could lead to an increased understanding of the risk factors associated 
with progression of the disease, thereby improving predictions as to which patients 
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are at risk of developing moderate to severe disease. Early diagnosis may also 
enable the identification of targets for future therapeutics, and potentially open the 
door for earlier treatment options aimed at halting CAVD progression that are not 
currently possible. For example, several pharmacologic interventions have been 
suggested to influence CAVD by targeting specific pathways such as the renin-
angiotensin system or oxidative stress. 56–58  
 
Figure 1.4: Example schematic of functionalizing SPIONs so that they can be used to 
bind to and target hydroxyapatite, a feature in the microcalcifications present in early 
CAVD. Note: not drawn to scale.  
 
The first step towards achieving this objective is the selection of a target suitable 
for early detection of CAVD. Out of many potential disease markers, we have 
selected hydroxyapatite (HA) – a crystalline calcium phosphate mineral that is also 
abundant in bone. Similar approaches can be found in the literature; Chin, et al. 
have recently published a review summarizing work that has examined calcium-
binding nanoparticles for vascular disease.59 HA is one of the main components in 












processes that are characteristic of CAVD.5,10,60 In addition, deposition of HA in the 
valve scales with disease severity, which is crucial to its utility as a target for a 
contrast agent capable of detecting disease earlier than is currently possible.61 
Although large HA deposits are found in severe CAVD, microcalcifications partially 
composed of HA are known to be present early in the disease (see Figure 1.2).34 
This makes HA the ideal target for the proposed contrast agent, since the presence 
of calcifications is a more specific marker of early stage CAVD than lipoprotein 
deposition or the presence of inflammatory markers or cells (e.g. macrophages).  
 
1.6 Specific Aims 
This dissertation is divided into three specific aims that focus on fabrication and 
characterization of HA-targeted SPIONs and their binding, MR, and medical 
properties. 
Aim 1: Fabrication and in vitro characterization of targeted SPIONs. For this aim, 
we have designed a fabrication schema that will result in HA-targeted and 
PEGylated SPIONs. Additionally, we have characterized the size and zeta 
potential of the SPIONs as well as the success of each functionalization step. 
Finally, we have characterized SPION binding to targeted and off-target surfaces, 
both with and without the presence of serum proteins. 
 
13 
Aim 2: Optimization of SPION binding and MR properties. For this aim, we have 
examined the impact of altering fabrication parameters of the SPIONs, including 
both their targeting peptide coating as well as the antibiofouling polymeric layer. 
These alterations were examined in light of either the ability of the SPIONs to bind 
to their target or the strength of the MR signal generated in order to optimize the 
fabrication process to produce nanoparticles with ideal binding and MR properties. 
Aim 3: Characterization of the medical properties of targeted SPIONs. For this aim, 
we have examined the impact of targeting peptide addition on MR signal and 
assessed whether binding to HA could be detected via MR. We have also 
examined the impact of HA-targeted SPIONs on the formation of crystalline HA in 
vitro, tested the ability of the particles to exhibit binding to HA in MR scan, and 
observed particle translocation through an endothelial layer, with successful 
binding to HA occurring subsequently. Finally, we have tested the ability of these 
targeted SPIONs to bind to HA in excised human valve samples.  
The findings reported in this dissertation provide a targeted, optimized MR contrast 
agent that may be capable of aiding in earlier detection of CAVD. In addition, the 
results from MR optimization of the particles have yielded important information 





Chapter 2: Fabrication and In Vitro Characterization of SPIONs62  
2.1 Introduction 
In order to produce HA-targeted SPIONs, a number fabrication and chemical 
functionalization steps must be undertaken (see Figure 2.1). Several methods of 
chemically functionalizing nanoparticle surfaces, thereby targeting them to specific 
cells or tissues, have been previously developed and described in the literature. 
These methods include functionalization of the nanoparticle surface with biological 
or biologically-derived molecules such as antibodies, peptides, or aptamers 
intended to interact with specific proteins.53,54,63–65 For some applications (e.g. 
cancer treatment) these specific interactions may be intended to cause uptake of 
drug-carrying nanoparticles into cells via receptor-mediated endocytosis.55,66–68 
For applications such as disease detection, it is simply necessary for the 
interaction between the targeting moiety and the target to cause association of the 
nanoparticle with the disease target.69,70 These studies will describe the 
development of a targeted SPION designed to associate with HA. 
In order to target HA, two peptides have been selected and tested for SPION 
functionalization (see Figure 2.1). The first is a modified hydroxyapatite-binding 
peptide (HABP) characterized by Roy et al. using ribosome display.71 The second 
is a modified and highly phosphorylated osteopontin-derived peptide (OPN) 
described and characterized by Hunter and Wang, et al.72,73 These two peptides 
were chosen because it was hypothesized that their different origins (synthetic vs. 
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biological) and different properties (due to their differing amino acid compositions) 
may confer distinct properties upon functionalized SPIONs. 
Figure 2.1: Schematic representing the fabrication and functionalization of HA-targeted 
SPIONs. A ligand exchange is performed on magnetic SPION cores coated in oleic acid 
to produce SPIONs coated in citric acid, and citric acid coated SPIONs are PEGylated 
using EDC/NHS chemistry. Targeting peptides HABP and OPN are added via an 
iodoacetyl/thiol interaction between iodoacetyl-PEG and peptides with cysteine residues. 
Specific methods are further discussed in Section 2.2. 
Although specific targeting via antibodies, peptides, or aptamers has shown high 
rates of success in vitro, these methods have often failed in vivo.74–76 One of the 
primary causes of in vivo failure is the formation of the so-called protein corona 
that occurs almost instantaneously upon exposure of nanoparticles to protein-rich 
media such as blood serum.77–79 The composition of the protein corona in terms of 
protein type, concentration, and conformation varies depending on the specific 
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surface functionalization of the nanoparticles,80,81 and can define their biological 
fate including biodistribution, cellular uptake, and immune response.82,83 
Additionally, the presence of the corona can block targeting moieties from 
interacting with their targets, causing a loss of targeting efficiency.84,85 Previous 
results in the literature indicate that the protein corona can inhibit the targeting 
capability of nanoparticles by as much as 94%, even in a solution that is only 10% 
serum.84 The protein corona consists of two layers: (1) the hard corona close to 
the nanoparticle surface, comprised of higher affinity proteins that may irreversibly 
bind to nanoparticles, and (2) the soft corona formed by loosely affiliated, lower 
affinity proteins that are reversibly bound and may exchange over time with 
proteins in the surrounding solution.86,87 It has been hypothesized that the hard 
protein corona, which is both closer to the nanoparticle surface and more tightly 
associated, may have a greater impact on nanoparticle targeting capabilities.82,88 
To prevent deposition of serum proteins, nanoparticles are commonly coated in an 
antibiofouling layer such as poly(ethylene glycol) (PEG) prior to the addition of 
targeting moeities.89,90 PEG is thought to display good resistance against 
nonspecific protein adsorption in large part due to its extensive formation of 
hydrogen bonds with surrounding water.91 However, recent findings have 
suggested that protein adsorption to the nanoparticle surface occurs even in 
nanoparticles that have been coated in PEG.92,93 Studies show that, even at low 
concentrations of serum (10%), protein deposition still occurs onto PEGylated 
nanoparticle surfaces.94 Given that blood is comprised of approximately 50-55% 
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protein-rich serum, this would present some obvious problems in the in vivo 
environment.  
Unlike many other targeted nanoparticles, HA-targeted SPIONs do not need to be 
taken up by cells in order to be efficacious. Although the specific protein-protein or 
peptide-protein interactions required for specific cellular uptake are highly 
susceptible to blockage by the protein corona,64,95,96 the effects of the protein 
corona have not been so thoroughly investigated for targeting strategies that do 
not require cellular uptake. In fact, targeting of non-protein disease features such 
as HA has not been examined at all.  
To test the ability of HA-targeted SPIONs to maintain specific targeting capabilities 
even in the presence of serum proteins, we conjugated the two different HA-
binding peptides (HABP and OPN) to PEGylated SPIONs and tested their binding 
properties in parallel. We assessed the specific and non-specific binding of these 
functionalized SPIONs in sodium phosphate buffer before characterizing the 
interaction of the nanoparticles with serum proteins in a 50% serum environment, 
to most accurately imitate the protein-rich in vivo environment. We additionally 
assessed the protein corona of the particles, to develop a better understanding of 
factors that may influence the ability of nanoparticles in general to bind to their 
targets in the presence of serum proteins.  
Our findings demonstrated that, while our peptide-coated SPIONs show 
substantial interactions with serum proteins and the immediate development of a 
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protein corona, the majority of the observed interactions with serum proteins are 
loose associations (i.e., part of a soft corona). This has allowed these peptide-
linked, HA-targeted SPIONs to maintain successful binding to HA even in the 
presence of serum. We hypothesize that this is due to the primarily charge-based 
interaction between the targeting peptides and HA,71,72 which may help to avoid 
some of the typical problems observed with relying on specific protein-protein 
interactions to allow for targeted binding in high-protein environments. The work in 
this chapter has implications in the selection of targets for future work on targeted 
nanoparticles, in addition to offering proof-of-concept that these HA-targeted 
SPIONs may have utility in the detection of CAVD. 
 
2.2  Materials and Methods 
Materials 
Iron tri(acetylacetonate), 1,2-tetradecanediol, oleic acid, oleylamine, dibenzyl ether, 
citric acid, diethyl ether, 2-methoxyethylamine, N-(3- Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC), N-Hydroxysuccinimide (NHS), 1,2-
dichlorobenzene, and N,N’-dimethylformamide were all purchased from Sigma-
Aldrich (St. Louis, Missouri). Human Umbilical Cord Vascular Endothelial Cells 
(HUVECs) and cell media were acquired from Lonza (Portsmouth, New 
Hampshire). When it was purchased (as indicated in the Results and Discussion 
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sections), HA powder was also purchased from Sigma-Aldrich (St. Louis, Missouri). 
All functionalized PEG reagents were obtained from Nanocs (Boston, 
Massachusetts).  Slide-A-Lyzer dialysis cassettes were acquired from Thermo 
Scientific (Rockford, Illinois). Fetal Bovine serum was obtained from Hyclone 
(Logan, Utah).  
All statistical analysis and figure generation were performed in R (version 3.5.1), 
and graphed using ggplot2.  
 
Iron oxide particle synthesis and surface modification 
Oleic acid-coated iron oxide nanoparticles were synthesized via high-temperature 
thermal decomposition as previously described.97 Briefly, the following reagents 
were mixed and stirred magnetically under nitrogen flow: 2mmol iron(III) 
tri(acetylacetonate), 10mmol 1,2-tetradecanediol, 6mmol oleic acid, 6mmol 
oleylamine, and benzyl ether. The resulting nanoparticles were precipitated in 
excess ethanol and pulled down using a magnet. The precipitated particles were 
washed with ethanol, dissolved in hexane, and centrifuged to remove aggregates. 
Oleic-acid coated SPIONs produced using this method were dried in a vacuum 
oven.  
A ligand exchange served to replace oleic acid with citric acid. Oleic acid-coated 
nanoparticles and citric acid were dissolved in a 1:1 mixture of dichlorobenzene 
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and N,N-dimethylformamide. The mixture was heated to 100˚C and left stirring for 
24 hours. Citric acid-coated nanoparticles (CA-SPIONs) were precipitated in 
diethyl ether and washed with acetone and diethyl ether before drying in a vacuum 
oven. 
CA-SPIONs were further coated with a layer of bifunctionalized PEG using a 
protocol similar to those previously described.97,98 CA-SPIONs were dissolved in 
pH 9 sodium phosphate buffer with desired amine-terminated PEGs, combined 
with N-hydroxysuccinimide ester (NHS) and 1-ethyl-3-(3-dimethylaminoproply) 
carbodiimide (EDC), and agitated for 24 hours at room temperature. For particles 
that would be further functionalized with HA-targeted peptides, PEG was added at 
a 1:4 molar ratio of NH2-PEG3.4k-iodoacetyl to NH2-PEG2k. SPIONs not 
functionalized to bind to HA were PEGylated with a 1:4 molar ratio of NH2-
mPEG3.4k to NH2-mPEG2k.  The resulting PEGylated SPIONs were purified by 
dialysis in all cases. 
Two different HA-binding peptides were purchased from Peptide 2.0 (Chantilly, 
Virginia). HA Binding Peptide (HABP – SVSVGMKPSPRPGGGKC) and an 
osteopontin-derived peptide (OPN - DDVDD(pT)DD(pS)HQ(pS)DEGGGKC) were 
linked to SPIONs via an iodoacetyl-thiol interaction to produce either HABP-
SPIONs or OPN-SPIONs. Peptides were added to iodoacetyl-PEG-SPION 
solutions in appropriate concentrations to target the addition of 25 peptide residues 
per SPION. Peptide addition reactions were allowed to run overnight at 4˚C, and 
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conjugated particles were purified from excess peptide by dialysis against 
deionized water at 4˚C. 
A schematic of the overall SPION functionalization process can be seen in Figure 
2.1 above. 
 
Dynamic Light Scattering, Zeta Potential, BCA Assay Characterization, and TEM 
The size and zeta potential of HA-SPIONs were measured via dynamic light 
scattering (DLS) in pH 9 sodium phosphate buffer. All measurements were made 
with a 90Plus Dynamic Light Scattering Analyzer (Brookhaven Instruments) at a 
90˚ detection angle. All samples were diluted 10x before measurement, as it has 
been previously indicated that high SPION concentrations may impact DLS 
readings.99 DLS measures the impact of nanoparticle movement on light scattered 
through a solution of small nanoparticles, and from these measurements, the size 
of the particles causing the light to scatter can be inferred. The bicinchoninic acid 
assay (BCA assay) was used to quantify success of peptide addition to SPIONs. 
For the BCA, each peptide (HABP or OPN) was used to construct a calibration 
curve (rather than the much-larger bovine serum albumin provided) in order to 
obtain a more accurate measurement of the quantity of peptide present. 
The shape and size of the SPIONs were examined on a JEOL 2100 (200 kV) 
transmission electron microscope (Tokyo, Japan). The samples were prepared by 
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placing a few drops of nanoparticle suspension onto a standard carbon-coated 
copper grid and then drying at ambient conditions. The TEM images were 
processed in ImageJ (NIH) to determine particle size and size distribution. All 
distinctly visible and easily delineated SPIONs in a given image were selected 
using the circular outline feature, and diameter was estimated by comparison to 
the scale bar (included in the images).   
 
In Vitro Binding Tests in Sodium Phosphate Buffer 
HA-SPIONs were shaken at room temperature (RT) for 30 minutes with HA in 
Costar Spin-X centrifuge tube filters over a range of HA quantities (0-200mg). After 
incubation, all samples were centrifuged at 3000 rpm for 3 minutes. The 
absorbance of the filtrate was measured at 510nm to determine the relative 
percentage of particles bound to the HA. Particles bound to HA cannot successfully 
pass through the filter, while unbound particles pass through easily. These 
experiments were repeated over a range of pH values (7.1-7.8). 
The specificity of HA-SPION binding to HA was tested by comparing results from 
HA binding tests with results from experiments testing off-target binding to 
cholesterol, collagen, fibrin, fibrinogen, and human vascular endothelial cells 
(HUVECs). All off-target binding surfaces were produced to target 25mg of the off-
target component per well, with the exception of HUVECs.  A collagen-coated six-
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well plate was used to test off-target HA-SPION binding to collagen, fibrin, and 
fibrinogen. For both the fibrin and fibrinogen gels, fibrinogen (Bovine plasma, 
Sigma-Aldrich) in pH 7.1 sodium phosphate buffer was incubated at RT for 10 
minutes to allow binding to the collagen surface coating. Thrombin in PBS (Bovine 
plasma, Sigma-Aldrich) was used to crosslink fibrinogen into a fibrin gel for 1 hour. 
For the HA-coated plates, a protocol similar to that developed by de Bruyn et al. 
was adapted;100 in short, two working solutions were prepared (12mM CaCl2 and 
7.5mM Na2HPO4), and were added in appropriate ratios to stoichiometrically yield 
25mg of HA (Ca10(PO4)6(OH)2) upon full conversion of the salt components to a 
crystalline form. These solutions were mixed and allowed to dry on top of the fibrin 
gels, producing a thin HA coating that effectively adhered to the plate. All wells 
were washed twice with buffer and allowed to dry under vacuum.  
Once the wells had dried, a 10x diluted SPION solution was added to each well 
and incubated for 30 minutes at RT. After incubation, samples were pulled from 
each well and filtered through a 0.2µm filter. The absorbance of each sample was 
measured at 510nm and compared to the absorbance of prepared samples of 
known SPION concentration or quantity to assess the number of SPIONs present 
after binding has been allowed to occur. 
To test HA-SPION binding to cholesterol, one well of a tissue culture-treated six-
well plate was filled with cholesterol in ethanol solution, and the ethanol was 
allowed to completely evaporate. After incubation, samples were pulled from each 
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well and filtered through a 0.2µm filter. The absorbance of each sample was 
measured at 510 nm and compared to the absorbance of prepared samples of 
known SPION concentration or quantity to assess the number of SPIONs present 
after binding has been allowed to occur.  
To test binding against HUVECs, the cells were cultured at recommended 
conditions in 6-well plates. After a week in culture, at which time the cells were 
observed to be confluent, cells were pre-incubated at 4ºC for 10 minutes to halt 
endosomal trafficking. 50µL of an HA-SPION solution was added to each well of 
the 6-well plate, and plates were incubated at 4ºC for 30 minutes. Absorbance at 
510nm was measured for samples of the media taken after incubation to determine 
the percentage of HA-SPIONs that remained in solution and did not adhere to 
HUVECs.  
 
SPION binding to Serum Proteins 
HABP-SPIONs, OPN-SPIONs, and PEG-SPIONs were each mixed 1:9 with a 50% 
fetal bovine serum (Hyclone) solution. The solution was transferred to a cuvette 
and allowed to sit at room temperature for 24 hours. DLS measurements were 
taken at specific time points (0 and 30 minutes; 1, 2, 4, 8, 12, and 24 hours) to 
observe any alterations in effective diameter of the SPIONs. These results were 
compared with samples that have been incubated similarly with DI water. These 




To assess the amount of protein bound to the SPIONs, HABP-SPIONs, OPN-
SPIONs, and PEG-SPIONs were each mixed 1:9 with 50% serum solution and 
incubated at room temperature for two hours. None of the prepared solutions 
showed visible signs of aggregation. All particles were washed by centrifugation 
3x to remove unbound serum proteins (17900g for 30 min at 4ºC) and resuspended 
in 200L of DI water. DI water was chosen as a diluent and resuspension agent in 
these studies because the presence of salt can screen the repulsion between 
nanoparticles and induce aggregation;101 for these studies, it was important to limit 
aggregation as much as possible during resuspension, in order to obtain an 
accurate final assessment of the final number of proteins per particle after all wash 
steps. Samples were removed after each washing step for subsequent protein 
measurement using the BCA assay, where they were compared to samples 
incubated in DI water as a control. Aliquots of samples incubated with either 50% 
serum or DI water and washed 3x were mixed 4:1 with Laemmli sample buffer and 
boiled in water for 5 minutes. These samples were loaded on a 4-20% Tris-glycine 
gel in Laemmli running buffer and resolved at 150V for 50 minutes at room 
temperature. After electrophoresis, the gel was fixed with 10% v/v acetic acid and 
30% v/v ethanol for at least 30 minutes and stained with silver nitrate stain (Pierce) 
according to the manufacturer’s protocol. The stained gel was scanned using a 
VersaDoc Scanner from Bio Rad and the scanned image is imported into ImageJ 
and cropped.  
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In Vitro Binding Tests in Serum 
Serum absorbs light at ~510nm, so an orthogonal method was used to measure 
SPION binding to specific surfaces in serum, although the protocol remained 
identical aside from the method of measurement. Plates were coated in cholesterol, 
collagen, fibrin, fibrinogen, and HA as previously described. All wells were washed 
twice with buffer and allowed to dry under vacuum.  
Each coated well was incubated in a 50% fetal bovine serum solution for 30 
minutes, while functionalized SPIONs (HABP-SPIONs, OPN-SPIONs, PEG-
SPIONs, and CA-SPIONs) were simultaneously incubated at room temperature for 
30 minutes. Serum was removed from the wells, and the SPIONs were diluted 1:9 
in a 50% serum solution and incubated on the coated wells for 30 minutes at room 
temperature. After incubation, the SPION solutions were removed and wells were 
washed with DI water. All wells were stained with a Prussian Blue stain to detect 
iron for 35 minutes. Wells were rinsed again, allowed to dry under vacuum, and 
imaged on an Axiovert S100 microscope. To quantify the number of particles 
remaining, these images were compared to images of these same, identically-
produced surfaces with known quantities of nanoparticles deposited on the 
surfaces. For example, images of fibrin surfaces with known quantities of PEG-
SPIONs deposited onto the surface were used to act as a “calibration curve” for 
experimental samples of PEG-SPIONs deposited onto fibrin surfaces. From this 
information for all unique combinations of functionalized SPIONs and surfaces, the 
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number of particles (as a function of the “image darkness” due to the stain) was 
estimated. Image greyscale analysis was performed in ImageJ. 
 
2.3 Results  
Iron oxide particle synthesis and surface modification 
SPIONs cores, produced by high temperature thermal decomposition, have a core 
size of ~10nm as confirmed by TEM (Figure 2.2).  
 
SPIONs produced by high-temperature thermal decomposition are coated in oleic 
acid (Figure 2.1), which is highly hydrophobic. The ligand exchange was 
performed with citric acid to produce hydrophilic SPION cores (CA-SPIONs) that 
can be further functionalized by well-characterized methods utilizing the large 
number of available carboxylic acid residues present on the modified SPION 
surface. CA-SPIONs were further functionalized with PEG, which acts as an 
antibiofouling agent. A heterobifunctionalized iodoacetyl-PEG-NH2 was selected 
to allow for subsequent functionalization of PEGylated particles with either HABP 
or OPN. 
Figure 2.2: TEM image of ~10nm 
SPION cores. SPION core sizes 
were quantified in ImageJ, which 
yielded an average core size of 





Dynamic Light Scattering, Zeta Potential, BCA Assay Characterization, and TEM 
Successful coating of SPIONs with citric acid, PEG, and desired peptides was 
confirmed by DLS results, zeta potential measurements, and the BCA assay 
(Table 2.1). CA-SPIONs are expected to be the smallest in size, with size 
increasing at every step of functionalization. Additionally, CA-SPIONs are 
expected to be highly negatively charged due to the presence of multiple carboxylic 
acid residues around the core. PEGylated SPIONs are expected to have a zeta 
potential closer to neutral, which was confirmed (Table 2.1).  
 
Fabrication Stage Effective Diameter (nm) Zeta Potential (mV) 
CA-SPIONs 13.2 -35.1 
PEG-SPIONs 19.2 -11.4 
HABP-SPIONs 20.5 -30.8 
OPN-SPIONs 25.1 -31.3 
 
Table 2.1: DLS and zeta potential measurements of SPIONs at various stages of 
fabrication indicate success of functionalization. As expected, particle size increased with 
the addition of each surface modification. Additionally, zeta potential changes reflect the 
change in surface groups at each stage. Data presented as mean of 3 independent runs 
of particle fabrication. 
 
Successful conjugation of either peptide (ribosome-display derived HABP or 
osteopontin-derived OPN) was confirmed via the BCA assay. BCA assay results 
yield a peptide concentration value for a given solution of peptide-coated SPIONs; 
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this peptide concentration, along with the measured quantity of SPIONs in the 
solution, was used to calculate the approximate number of peptides per SPION. 
Because the conjugation reaction was performed to target 25 peptides per SPION, 
we were able to calculate from these results an approximate reaction efficiency 
and approximate number of peptides conjugated per SPION. BCA assay results 
after peptide addition indicate a 72% reaction efficiency for the addition of HABP 
to SPIONs (~18 peptides/SPION) and a 92% reaction efficiency for the addition of 
OPN to SPIONs (~23 peptides/SPION).  
HABP and OPN properties were evaluated using the online tool available from 
GenScript.102 Properties of the peptides are summarized below (Table 2.2). 
 
Property HABP OPN 
Isoelectric Point 10.79 3.58 
Charge 3 -6 
Attribute Basic Acidic 
Number of Hydrophobic Residues 6 1 
 
Table 2.2: Summary of the peptide properties of both HABP and OPN. As expected, the 
peptides have different chemical properties due to their differing amino acid sequences. 
These properties may play an important role in functionalized SPION behavior. In 
particular, the differences in charge and number of hydrophobic residues are likely to 




In Vitro Binding Tests in Sodium Phosphate Buffer 
Functionalized SPION binding to HA was evaluated in sodium phosphate buffer 
via an in vitro assay developed for this purpose (Figure 2.3). HA-targeted SPIONs, 
coated with either HABP or OPN, bind to HA in centrifugal filter tubes in a dose-
dependent manner as expected – e.g. the solution in the tube farthest to the left 
(0mg of HA) is much darker in color than the solution in the tube farthest to the 
right (200mg HA), indicating that fewer nanoparticles remain unbound and in 
solution with increasing quantities of HA (Figure 2, A and B). HABP-SPIONs bind 
in significantly (p < 0.05) higher quantities than OPN-SPIONs to comparable 
amounts of HA at lower quantities of HA.  
 
Figure 2.3: (A) Binding of HABP SPIONs to HA. From left to right, tubes contain 0, 5, 10, 
25, 50, 100, and 200mg of HA. After filtration of the hydroxyapatite, the concentration of 
SPIONs remaining in the tubes is visibly different depending on the amount of HA in each 
tube – higher quantities of HA result in fewer particles remaining unbound. (B) 
Quantification of SPION binding from samples bound in the same setup as that illustrated 
in (A). Generally, 50mg of HA was sufficient to fully bind 9.5 x 1013 HABP-SPIONs, and 
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7.7 x 1013 OPN-SPIONs. (C) Quantification of HABP- and OPN-SPION binding to various 
biologically-relevant surfaces. HA-targeted SPIONs bind significantly more to HA than to 
other surfaces tested, although some degree of off-target binding did occur. Error bars are 
standard deviation; n=3.  
 
For the studies in Figure 2.3A and B, powdered HA was purchased from Sigma. 
This purchased form of HA does not lead to issues with the centrifugal filtration 
used for these experiments. Equal flow of liquid through the filter upon 
centrifugation is observed in all samples (Figure 2.3A); only the quantity of 
nanoparticles, assessed via an absorbance assay, differs. On the other hand, HA 
as formed by evaporation of mixed calcium and phosphate solutions lead to issues 
with filtration in the centrifugal filter tubes, but not in the syringe filters (data not 
shown). Therefore, for Figure 2.3C, the evaporation method was preferred, as this 
method is more likely to produce the mix of crystalline HA and amorphous, 
insoluble calcium phosphate that is more reflective of what may be found 
biologically.103,104 
SPIONs suspended in sodium-phosphate buffer do not exhibit binding to other 
biologically-relevant off-target molecules (Figure 2.3C). These experiments were 
performed by coating the surface of cell culture plates in biologically-relevant 
substances (cholesterol, collagen, fibrinogen, fibrin, or HUVECs) and allowing 
binding to occur. For these studies, all surfaces (including HA) were fabricated 
such that there were ~25mg (or as close as possible to this target) of each material 
present for binding tests. For HUVECs, these studies were performed once 
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HUVECs reached confluence. The number of SPIONs was determined by 
comparing the absorbance of the filtrate to the absorbance of solutions with known 
quantities of nanoparticles. This method was chosen to account for any potential 
differences in the starting concentrations of the various nanoparticle solutions used. 
Low levels of non-specific binding are expected and observed, but binding to HA 
occurs at much higher levels; at least 5.23x and 4.28x more for HABP- and OPN-
SPIONs, respectively. Binding to HA occurs significantly more than binding to all 
off-target surfaces for both HABP- and OPN-SPIONs (p < 0.05). 
It has been suggested that both HABP and OPN binding to HA is charge-
mediated.71,72,105 Therefore, HABP- and OPN-SPION binding to HA was assessed 
in sodium phosphate buffer at different pH levels (Figure 2.4). The pH levels of 
7.1, 7.4, and 7.8 were selected because they may be physiologically relevant; pH 
levels in this range can be detected close to plaques in atherosclerotic disease.106 
The different pH levels tested do not significantly impact HABP- or OPN-SPION 
binding to HA in terms of binding quantity; however, higher pH levels appear to 
lead to more variability in binding strength of SPIONs to HA. For example, for 50mg 
of HA, the standard deviations across runs at pH 7.1 are 2.05 and 11.96 for HABP- 
and OPN-SPIONs, respectively. At pH 7.4, those standard deviations are 17.14 




Figure 2.4: Quantification of the assessment of the impact of pH on SPION binding to HA 
in sodium phosphate buffer. Different pH values tested were: (A) 7.1, (B) 7.4, and (C) 7.8. 
Set-up for these experiments is equivalent to the set-up for results shown in Figure 2.3, 
(A) and (B). Error bars are standard deviation; n = 3. 
 
SPION binding to Serum Proteins 
Like most if not all other nanoparticles, these functionalized SPIONs are expected 
to show binding to serum proteins. To assess the interactions of functionalized 
SPIONs with serum proteins, PEG-SPIONs as well as HABP-SPIONs and OPN-
SPIONs were incubated with a 50% fetal bovine serum solution for 24 hours, and 
compared with SPIONs incubated in DI water to observe differences in apparent 
diameter that would indicate association with serum proteins (Figure 2.5). For 
these experiments, PEG-SPIONs were tested in addition to HA-targeted SPIONs 
in order to evaluate whether the effects shown were due specifically to the 
presence of the peptides. Results indicate that HABP-, OPN-, and PEG-SPIONs 
all associate with serum proteins immediately upon incubation. Samples develop 
an apparent protein corona as soon as serum is added to the nanoparticle solution. 
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This corona does not significantly alter in size (p > 0.05) over 24 hours in any case.  
 
 
Figure 2.5: Fold change in nanoparticle size over time in a 50% serum solution. (A) HABP-
SPIONs, (B) OPN-SPIONs, and (C) PEG-SPIONs were all tested under identical 
conditions. Both targeted (HABP- and OPN-SPIONs) and non-targeted (PEG-SPIONs) 
bind to proteins in serum, as evidenced by changes in effective particle diameter upon 
exposure to 50% serum. The protein corona that developed around all 3 functionalized 
SPIONs tested did not appear to alter significantly over the course of a 24-hour incubation. 
HABP-SPIONs appear to accumulate the largest protein corona, while OPN-SPIONs have 
the smallest. Despite the intended anti-biofouling function of PEG, PEG-SPIONs do still 
appear to accumulate a protein corona in 50% serum. Error bars are standard deviation; 
n = 3. 
 
However, there are observed differences in the size of the associated protein 
corona depending on the SPION coating. HABP-SPIONs exhibit the largest 
effective diameter in 50% serum (4.64 – 5.28x the diameter in water). OPN-
SPIONs have the smallest effective diameter in 50% serum (2.88 – 3.09x the 
diameter in water). PEG-SPIONs also demonstrate a substantial alteration in 
effective diameter in 50% serum (3.55 – 3.98x the diameter in water). 
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To better understand the protein corona of HABP-, OPN-, and PEG-SPIONs, 
several follow-up experiments were performed. Firstly, the formation of the protein 
corona in solutions of different pH was assessed (Figure 2.6). For these 
experiments, the pH of a 50% serum solution was altered over a broad range (pH 
6-9), and functionalized SPIONs were added to each solution. The effective 
diameters of each SPION sample were analyzed by DLS. Diameters were 
normalized to the effective diameter of that particular functionalized SPION at a 
pH of 7.4, i.e. the pH of unaltered 50% serum solution. Altering the pH of the 50% 
serum solution does not appear to significantly impact the effective diameter of 
SPION samples (p > 0.05), although average diameters shifted non-significantly 
with changes in pH.  
 
Figure 2.6: Assessment of (A) HABP-SPION, (B) OPN-SPION, and (C) PEG-SPION 
effective diameter in 50% serum at different pH values. All measurements were 
normalized to the diameter of particles in 50% serum at pH 7.4. Error bars are standard 
deviation, n = 3. 
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Subsequently, SPIONs were incubated for different amounts of time (0 minutes, 
30 minutes, and 2 hours) with 50% serum and subjected to 3 wash steps via 
centrifugation (Figure 2.7). These times were selected for their clinical relevance; 
patients may be administered a contrast agent some time prior to clinical MR, but 
that time does not typically exceed 2 hours.107,108 DI water was chosen as a diluent 
and resuspension agent in these studies because the presence of salt can screen 
the repulsion between nanoparticles and induce aggregation;101 for these studies, 
it was important to limit aggregation as much as possible during resuspension, in 
order to obtain an accurate assessment of the final number of proteins per particle 
after all wash steps. 
Proteins still associated with the nanoparticles after 3 washes are considered to 
be tightly associated (i.e., part of a “hard” corona), while those that were removed 
with wash steps are considered to be more loosely associated (i.e., part of a “soft” 
corona). Samples were taken after each wash, and the BCA assay was used to 
determine the amount of protein that remained associated with the particles. In all 
cases, the amount of associated protein is significantly reduced (p < 0.05, 
reduction by at least 10.78x with no incubation, at least 3.26x with 30 minutes of 
incubation, and at least 2.82x with 2 hours of incubation) after just one wash, with 






Figure 2.7: Soft and hard protein corona measured as mg of associated protein per 
particle after incubation in a 50% serum solution for (A) 0 minutes, (B) 30 minutes, and (C) 
2 hours, followed by 3 wash steps via centrifugation and resuspension in DI water. Protein 
associated with the particles with no wash steps is considered to be part of the soft corona; 
protein associated with the particles after 3 washes is considered to be part of the hard 
corona. Error bars are standard deviation; n=3.  
 
After 3 washes, PEGylated SPION samples that have been incubated in 50% 
serum for 0 or 30 minutes show increased protein in comparison to HABP- and 
OPN-SPIONs (for no incubation in comparison to OPN-SPIONs, and 30 minutes’ 
incubation with both HABP- and OPN-SPIONs, this difference is significant, with p 
< 0.05).  
As might be expected, samples that were incubated for 2 hours show an increased 
level of protein in the hard corona in comparison to samples that were incubated 
for 0 and 30 minutes (Figure 2.7C). There are statistically significant (p < 0.05) 
differences in the amount of protein per particle left after 3 washes for HABP- as 
well as OPN-SPIONs that had been incubated for 0 and 30 minutes in comparison 
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to those that had been incubated for 2 hours. However, the amount of protein in 
the hard corona for PEGylated samples does not change significantly (p > 0.05).  
The protein corona of HABP-, OPN-, and PEG-SPIONs after 3 washes was 
additionally qualitatively examined by SDS-PAGE gel electrophoresis followed by 
silver nitrate staining (Figure 2.8). These results can be compared to samples that 
had not been incubated with serum (Figure 2.8A). The darkness of the banding of 
the PEGylated SPION samples (rightmost well of each gel in Figure 2.8 B, C, and 
D) in comparison to all other samples reflects the increased number of PEGylated 
SPIONs that were successfully pelleted with each was step. Qualitatively, 
PEGylated SPIONs formed a pellet more readily than HABP- and OPN-SPIONs 
upon centrifugation, and were more difficult to redisperse in water with each wash. 
This is likely the result of some degree of hydrophobic interactions between PEG 




Figure 2.8: SDS-PAGE gels stained with silver nitrate. (A) Samples (HABP-, OPN-, and 
PEG-SPIONs, respectively) that were not incubated with serum. Wells in (B), (C), and 
(D) are samples (HABP-, OPN-, and PEG-SPIONs in each well, respectively) that were 
incubated with serum, washed 3x with water by centrifugation, and then mixed with an 
SDS-based running buffer and boiled to denature any protein remaining attached to the 
particles. Differences between wells reflect differences in which proteins may have 
preferentially adsorbed to different surface functionalizations; differences between gels 
reflect potential differences in the hard protein corona with longer incubations times. 
Samples were incubated with serum for: (B) 0 minutes, (C) 30 minutes, and (D) 2 hours 
prior to beginning the wash steps.  
 
Beyond this, it is possible to observe some differences between preferentially 
adsorbed proteins to HABP-, OPN-, and PEGylated SPIONs, both within a single 







In Vitro Binding Tests in Serum 
Finally, binding of HABP-, OPN-, and PEG-SPIONs both to HA as well as off-target 
surfaces was evaluated in 50% serum (Figure 2.9). Despite the fact that HABP- 
and OPN-SPIONs exhibit binding to serum proteins, they still demonstrate targeted 
binding to HA. Binding to HA occurred at a rate 5.97x greater than binding to any 
off-target surface for HABP-SPIONs, and 4.00x greater for OPN-SPIONs. Off-
target surfaces evaluated include: cholesterol, collagen, fibrin, and fibrinogen. 
HUVECs were not tested in the experiments due to concerns that a rapid increase 
in environmental serum concentrations would impact membrane transport of the 
cells due to a rapid change in environmental osmolarity.110,111 For these studies, 
PEG-SPIONs as well as CA-SPIONs were evaluated as negative controls to 
ensure that any binding trends observed in the targeted SPIONs were due to the 






Figure 2.9: (A) Images taken at 20x of Prussian-Blue stained SPIONs bound to different 
surfaces to observe specific vs. non-specific binding. (B) Quantification of multiple runs 
of binding assays (n = 3) demonstrate that both HABP- and OPN-SPIONs bind at 
significantly higher rates to HA than other biologically relevant surfaces, while PEG-
SPIONs do not bind significantly to HA. PEG-SPIONs exhibit significant off-target 
binding to cholesterol, potentially due to the hydrophobic nature of the cholesterol 
surface.  
 
Because HA needs to be coated on a fibrin layer to successfully stick to the plates, 
and because both HABP- and OPN-SPIONs exhibit some off-target binding to 
fibrin, it is likely that some of the particles in the HA wells are bound to fibrin rather 
than HA. However, the observed binding results for fibrin occur when the particles 
were interacting directly with an unaltered fibrin surface, not with a fibrin surface 
that has been blocked by a crystalline HA layer. Therefore, the vast majority of 
observed binding to HA is likely to the HA itself, with a small contribution from the 
underlying fibrin layer.  
One notable observation of the results in Figure 2.9B in comparison to earlier 
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binding studies (Figure 2C) is that the variability of targeted and non-targeted 
SPION binding in serum appears to be much greater than the variability in sodium 
phosphate buffer. For example, in serum, between 0 – 3.43 x 1012 HABP-SPIONs 
bind to fibrin; in sodium phosphate buffer, that range is 0.62 x 1012 – 1.33 x 1012. 
In serum, between 0 – 4.27 x 1012 OPN-SPIONs bind to fibrin; in sodium phosphate 
buffer, that range is 1.22 x 1012 – 1.46 x 1012. This is perhaps unsurprising. 
However, even with this variability, binding of HABP- and OPN-SPIONs to HA is 
still significantly greater than off-target binding (p < 0.05).  
 
2.4 Discussion 
Functionalized SPIONs have successfully been fabricated using the scheme 
illustrated in Figure 2.1. The ~10nm SPION core size, as confirmed by TEM 
(Figure 2.2) was selected to reflect the size of SPIONs that are often developed 
for MR applications in the literature.38,112,113 SPIONs may be grouped into three 
categories based on their size: (1) standard SPIONs (5-180nm), (2) ultrasmall 
SPIONs (10-50nm), and (3) very small SPIONs (<10nm).114 The 10nm core size 
was chosen because the most commonly used MRI agents are ultrasmall SPIONs; 
subsequent to all coating steps described, SPIONs with a core size of ~10nm 
remain categorized as “ultrasmall.”112  
The ligand exchange with citric acid prior to PEGylation is one of a wide variety of 
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PEGylation methods demonstrated in the literature. This method was selected in 
part because the CA-SPION cores are themselves soluble in water, making 
characterization, storage, and subsequent PEGylation more facile than other 
PEGylation methods which largely rely on coating of hydrophobic, oleic-acid 
coated cores.  
Coating with PEG was performed to aid in making these SPIONs “stealth” 
nanoparticles by preventing protein deposition and therefore recognition by the 
immune system.89–91 Additionally, previous studies have indicated that polymer 
coatings such as PEG or dextran can help increase the circulation time of SPIONs 
after injection.115,116 However, claims that PEG prevents the deposition of all serum 
proteins have been refuted or confounded by many recent studies showing that 
proteins present in blood or serum bind to PEGylated nanoparticles.92,93 
Nevertheless, PEG was used in part to also allow the addition of a specific binding 
site for peptides.  
Two peptides were selected for binding studies to HA, as they are expected to 
have widely different properties. Ribosome-derived HABP is a synthetic peptide 
that, in addition to binding to HA, may show some binding to metallic surfaces.117 
OPN is a highly-phosphorylated peptide that has been derived from osteopontin, 
a bone-binding sialoprotein that plays roles in biomineralization, bone remodeling, 
and various immune functions.118–120 Although both of these peptides bind to HA, 
characterization of these peptides in silico via an online tool from GenScript yields 
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the results summarized in Table 2.2, which indicate that the peptides have vastly 
different properties and are likely to behave very differently in solution. In particular, 
the acid/base nature, charge, and hydrophobicity of the peptides varies 
substantially. These differences in properties have notable impacts even in in vitro  
binding studies (Figure 2.3). Although both HABP- and OPN-SPIONs 
demonstrated binding to HA (Figure 2.3B), the increased binding of HABP-
SPIONs at lower quantities of HA reflects a difference that likely reflects a 
difference in HABP and OPN interaction with HA. Importantly, however, both 
HABP- and OPN-SPIONs bind to small quantities  
(< 200mg) of HA. This was of particular concern, as this is a relevant quantity of 
HA in early cardiovascular disease.61  
The differences in effective diameter observed upon exposure of functionalized 
SPIONs to serum proteins (Figure 2.5) are likely due to a combination of factors. 
HABP-SPIONs show the largest increase in effective diameter, indicating either 
that larger proteins are preferentially binding, more proteins are bound, more 
aggregation is occurring, or likely, some combination of all three factors. This may, 
in part, be due to the synthetic nature of the peptide, which, as its sequence was 
determined by ribosome display, is unlikely to have biological analogs. On the 
other hand, OPN-SPIONS showed the smallest increase in diameter, potentially 
indicating that fewer serum proteins tend to associate with these particles, or that 
less aggregation occurs. Despite the fact that PEG is intended to prevent 
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deposition of serum proteins, PEG-SPIONs without the addition of either peptide 
also demonstrate a substantial alteration in effective diameter in 50% serum. This 
indicates that serum proteins do adhere to or associate with PEGylated 
nanoparticles, as has been previously reported by other groups.92,93 The vast 
majority of these interactions with serum protein are likely to be non-specific, as 
partially indicated by the fact that altering the pH does not significantly change the 
effective diameter of the SPIONs in serum (Figure 2.6). If the observable protein 
corona were the result of specific and strong binding interactions, it is likely that 
such large alterations in pH would disrupt these interactions, and a change in the 
size of the protein corona or the resulting zeta potential would be observed. 
The fact that the protein corona is mostly nonspecific and does not substantially 
alter in size over the course of 24 hours in Figure 2.5 does not necessarily indicate 
that it remains constant. It is well accepted that the nanoparticle corona is made 
up of a “hard” corona that consists of tightly bound proteins that and is unlikely to 
change significantly in composition over time, and a “soft” corona that consists of 
proteins that are associated with low affinity that may readily adsorb and desorb 
over time. Figure 2.7 aims to visualize some of these changes. Changes observed 
across incubation times (0 hours, 30 minutes, and 2 hours) are reflective of 
alterations in the hard vs. soft protein corona. These results corroborate some of 
the findings from Figure 2.5; specifically, that the association of serum proteins 
with all SPIONs occurs immediately upon mixing of the nanoparticles with serum. 
Additionally, these results support previous literature, demonstrating that 
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PEGylated particles do show reduced protein association in comparison to 
SPIONs with attached peptide prior to any performed washes. However, while 
there may be less of a “soft” protein corona associated with PEGylated particles, 
there is an increased protein presence in the “hard” protein corona; barely any 
protein remains associated with HABP- or OPN-SPIONs after 3 washes for 
samples that have been incubated for 0 or 30 minutes. Ultimately, the difference 
between 2 hour and 0 hour/30 minute samples for HABP- and OPN-SPIONs does 
indicate an increased quantity of protein per SPION with longer incubation. This 
may suggest a decreased targeting efficiency in peptide-coated SPIONs upon 
longer incubation with serum.  
Qualitative visualization of some of these results in Figure 2.8 shows similar trends, 
in addition to some differences observed between samples in terms of the types 
of proteins bound to the SPIONs. The differences within a gel are to be expected; 
many previous studies have confirmed that different surface functionalizations 
yield an ultimately different protein corona composition.121,122 The differences 
between gels would confirm previous results in the literature, which have found 
that, with incubation, loosely associated proteins close to the nanoparticle may be 
replaced by different proteins that more preferentially associate with a given 
surface functionalization.88 The types of protein associated with each particle were 
not further assessed, as these experiments were performed in 50% fetal bovine 
serum, and specific protein analysis may not be comparable or relevant for medical 
applications in humans. Additionally, it has been shown that factors such as shear 
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stress (which would be experienced by SPIONs in circulation) contribute to 
observed differences in the protein corona formed on nanoparticles.123 Because of 
this, and the matrix chosen, it was determined that assessing the exact 
composition of the corona would not yield medically relevant results for these 
particles. Further studies would be needed to assess targeted binding both in 
human serum as well as under flow conditions; yet even these studies could not 
fully recapitulate the in vivo environment. 
Finally, despite the presence of 50% serum, HABP- and OPN-SPIONs do still bind 
to HA significantly more than they bind to any off-target surfaces. For these studies 
(Figure 2.9), CA-SPIONs in addition to PEG-SPIONs were examined as a control. 
Because CA-SPIONs, like HABP- and OPN-SPIONs, carry a highly negative 
surface charge, the results in Figure 2.9 would indicate that it is not merely the 
presence of a negative surface charge that causes the targeted binding of HABP- 
and OPN-SPIONs to HA, although charge may certainly play a role. 
The apparent off-target binding of PEG-SPIONs to cholesterol was unexpected, 
but is evident in microscopic images as well as the quantitative data. It is 
hypothesized that this binding may be due to the hydrophobic and crystalline 
nature of the deposited cholesterol. Similar results have been reported previously 
for cyclodextrin-coated nanoparticles.124,125 For diseases such as atherosclerosis, 
it may be worth further examining the interaction between PEGylated nanoparticles 
and cholesterol in the future.  
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Chapter 3: Optimization of SPION Binding Properties and MR Signal 
3.1 Introduction 
As described in Chapters 1 and 2, SPIONs are commonly used as contrast agents 
for clinical MRI.126–128 SPIONs hold specific advantages over widely-used 
gadolinium-based MR contrast agents in that each nanoparticle contains 
thousands of iron atoms and approaches saturation magnetization under a 
magnetic field typical for MR, meaning that each nanocrystal can generate signal 
contrast several orders of magnitude higher than gadolinium chelates.129 
Additionally, SPIONs have demonstrably lower toxicity in vivo than gadolinium-
based contrast agents.44,45,47,90,98 These two features make SPIONs well-suited in 
particular for early detection or diagnosis of diseases ranging from cancer to 
atherosclerosis, among many others. 
One challenge of using molecular-targeted, or more specifically, HA-targeted 
SPIONs as a method to detect early calcium deposits in CAVD is that, like many 
early-disease targets, these calcium deposits are typically present in small 
quantities. Detecting such small quantities of HA, even with the benefit of SPION-
enhanced contrast, is challenging in MRI. It is therefore desirable and necessary 
to synthesize SPIONs with substantial signal enhancement in order to improve the 
sensitivity of these diagnostic methods. This can be achieved in one of two ways: 
1) optimizing targeted SPION binding to HA, to ensure that as many SPIONs as 
possible can bind to the target, and/or 2) optimizing the targeted SPION makeup 
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to enhance MR signal of the particles themselves. However, few previous studies 
have comprehensively examined either approach to signal optimization. 
The first approach (optimizing targeted SPION binding to HA to ensure that as 
many SPIONs as possible can bind to the target) would rely primarily on changes 
to the peptide coating of the SPIONs. As HA-SPIONs and OPN-SPIONs did 
demonstrate different binding properties (notably, Figure 2.9B, although the 
difference is not statistically significant, and Figure 2.3B, where the differences for 
small quantities of HA are statistically significant), it was hypothesized that altering 
the targeted number of peptides per SPION may also impact the number of 
SPIONs bound to a given quantity of HA. It was also hypothesized that combining 
HABP and OPN onto a single SPION, and altering the ratio of HABP:OPN peptides 
on a single SPION, may impact the number of SPIONs bound to HA as well. These 
hypotheses were tested using methods described below.  
The second approach (optimizing the targeted SPION makeup to enhance MR 
signal of the particles themselves) would rely primarily on changes to the PEG 
coating and SPION core size that may yield corresponding changes in the MR 
signal of the SPIONs. SPIONs create contrast in MR imaging by affecting the 
relaxation properties of nearby protons; namely T1 (spin-lattice) and T2 (spin-
spin).130 The corresponding relaxivities r1 and r2, i.e., the change in relaxation rates 
of water protons with respect to particle concentration are in part determined by 
the translational diffusion of the water molecules in the inhomogeneous magnetic 
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field caused by the SPIONs.129 Although SPIONs impact both r1 as well as r2 
relaxivities, they are primarily used as T2 contrast agents because of their larger r2 
relaxivities. Two parameters of the SPIONs and their chemical coatings are known 
to impact the MR signal generated by the particles: (1) iron oxide core (size and 
material), and (2) the polymer coating surrounding the SPION core, which includes 
coating density (i.e. polymer chains per nm2), thickness (polymer chain length), 
and chemical composition.  
Some prior work has explored the former aspect of SPION contrast agents. It is 
known that for a fixed total amount of iron in the core, r2 relaxivity of SPIONs 
increases with the magnetization and the total core size (i.e. iron oxide plus other 
elements that may be added to the core).131,132 Altering the magnetization of 
SPIONs by doping the iron oxide with other magnetic elements (e.g. nickel, cobalt, 
and manganese) leads to enhancement of the measured relaxivities of the 
SPIONs.132–134  
However, the effect of changes in polymer coating in terms of density, thickness, 
and chemical composition on the resulting MR properties of the SPIONS not been 
well-characterized to date. Of the limited prior studies, none have controlled for or 
measured coating density, which is thought to have a direct effect on the resultant 
relaxivities of the agent.98,135 The relevance of understanding how altering the 
SPION core coating may impact MR signal is in part due to the fact that the 
strength of the magnetic field surrounding the SPION core diminishes rapidly with 
 
51 
distance; thus, the strongest part of the magnetic field surrounding the SPION 
often falls within the polymer coating.135,136 SPION functionalization using different 
coating schemes, particularly in terms of method of chemical attachment of the 
coating to the core and polymer chain length, may affect their MR properties even 
if the coating density remains constant. The aim of the MR studies presented in 
this chapter is to determine the effect of different methods of chemical attachment 
of a polymer, polymer chain length, and polymer coating density on the MR 
relaxivities of SPIONs, thereby contributing a better understanding of the 
interaction of these parameters and the efficacy of the designed agent. These 
results will aid in better optimization of SPION MR properties in the future, with the 
aim of improving SPION contrast agents intended for clinical imaging.  
The results of the experiments performed in this aim will aid in the signal 
enhancement and/or optimization of HA-targeted SPIONs for use in early detection 
of CAVD. These results will aid in the selection of an optimized coating schema, 
from the standpoint of both the peptide and polymer coatings.  
 
3.2 Materials and Methods 
A number of SPIONs were synthesized to be physiochemically distinct in terms of 
their core size, PEG chain length, and the method of PEG attachment to the SPION 
core. SPION properties including size, zeta potential, and coating density of the 
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attached PEG were evaluated. The MR relaxivities of these SPIONs were 
subsequently measured and compared.  
 
Materials 
Materials previously discussed in Chapter 2 were obtained from the same sources. 
NH2-PEG and 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) – PEG 
reagents were obtained from Nanocs (Boston, Massachusetts); phosphine oxide 
(PO)-PEG  reagents were obtained from JenKem Technology (Plano, Texas).   
Cryogenic vials for sample measurements were obtained from Corning (Corning, 
New York).   
 
Altering the number of peptides or the peptide ratio per SPION 
Iodoacetyl-PEG-SPIONs are fabricated as previously described in Chapter 1. To 
alter the number of peptides bound per SPION, HABP or OPN peptides are added 
to iodoacetyl-PEG-SPION solutions in appropriate concentrations to target the 
addition of 5, 10, 25, 50, and 100 peptide residues per SPION. To alter the peptide 
ratio per SPION, solutions of combined HABP and OPN are added to iodoacetyl-
PEG SPION solutions in appropriate concentrations to target the addition of a 1:2, 
2:1, and 1:1 ratio of HABP:OPN peptide residues, all targeting the addition of 25 
total peptides. Peptide addition reactions are allowed to run overnight at 4˚C, and 
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conjugated particles are purified from excess peptide by dialysis against deionized 
water at 4ºC. In vitro binding tests in sodium phosphate buffer are performed on 
these samples with powdered HA from Sigma, as previously described in Chapter 
2. Statistical analysis and graphing of the results were performed in R.  
 
PEGylation 
PEGylation of OA-SPIONs was accomplished via one of three protocols similar to 
the majority of those that have been previously used to functionalize SPIONs (see 
below). 
1) PO-PEGylation:137 OA-SPIONs are dissolved in 1mL of n-heptane or 1mL of 1,2 
dichlorobenzene while PO-PEG (molecular weight 1, 2, or 5 kDa) is dissolved in 
1mL of ethanol. Sufficient PEG is used to target a coating density of 0.70nm-2. The 
mixture is heated (70ºC) and left stirring for at least 5 hours. PO-PEG coated 
nanoparticles (PO-PEG-SPIONs) are precipitated in n-hexane and collected on a 
magnet. They are then redispersed in ethanol before dispersing in DI water and 
remaining ethanol is allowed to evaporate. Excess PEG is removed by dialysis for 
at least 48 hours against DI water.  
2) NH2-PEGylation:97,98 A ligand exchange is performed to replace the oleic acid 
with citric acid. Oleic acid-coated nanoparticles and citric acid are dissolved in a 
1:1 mixture of dichlorobenzene and N,N-dimethylformamide. The mixture is heated 
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to 100ºC and left stirring for 24 hours. Citric acid coated nanoparticles (CA-SPIONs) 
are precipitated in diethyl ether and washed with acetone and diethyl ether before 
drying in a vacuum oven. 
For PEGylation, CA-SPIONs are dissolved in pH 9 sodium phosphate buffer and 
filtered using syringe PTFE filters (0.2 µm). NH2-PEG (molecular weight 1, 2, or 5 
kDa) is added to the CA-SPIONs in quantities sufficient to target a coating density 
of 0.70nm-2. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) are added in molar excess to the solution, which is 
allowed to mix overnight at room temperature. Excess PEG is removed by dialysis 
for at least 48 hours against DI water.  
3) DSPE-PEGylation:135 OA-SPIONs are dissolved in chloroform. A corresponding 
polymer solution is created through the dissolution of DSPE-PEG (molecular 
weight 1, 2, or 5 kDa) in a 1:1 mixture of chloroform and acetonitrile in quantities 
sufficient to target a coating density of 0.70nm-2. The two solutions are mixed for 
15 minutes while 10mL of water and two washed marbles are warmed to 70ºC. A 
rotary evaporator is used to remove the chloroform and acetonitrile, creating a thin 
film of particles and PEG on a roundbottom flask. The water and marbles are then 
added to the flask and swirled vigorously for 15 minutes until the film is dissolved. 
Once mixed, the solution is filtered through a 0.2µm syringe filter. DSPE-
PEGylated nanoparticles are separated from DSPE-PEG micelles or liposomes by 
pulling down onto a magnet. The isolated DSPE-SPIONs are redispersed in water. 
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Dynamic Light Scattering, Zeta Potential, and Thermogravimetric Analysis 
The effective diameter of all SPIONs produced is measured via dynamic light 
scattering (DLS) in water. Samples are diluted 10x in water and measured on a 
90Plus DLS Analyzer (Brookhaven Instruments) at a 90˚ detection angle. Dilution 
was performed because previous studies have indicated that high concentrations 
of nanoparticles may disrupt DLS readings.138 Zeta potential measurements are 
performed on the same samples using the same apparatus. 
The density of polymer coating is measured by thermogravimetric analysis (TGA) 
using a Discovery TGA system (TA Instruments). Samples are lyophilized to 
remove all water, and at least 1mg of each sample for each run is loaded onto a 
TGA pan. All TGA analysis is performed under nitrogen flow. Samples are ramped 
to 100°C and allowed to equilibrate to remove any additional water that may have 
been absorbed by samples during storage. Then, samples are ramped to 650°C 
and allowed to equilibrate. The mass remaining at the end of this ramping step is 
considered to be solely comprised of the iron oxide core of the particles; these 
values are used to calculate the amount of PEG that was attached to the particles 





Preparation of Samples for MR Measurements 
The iron concentration in each resulting solution containing PEGylated particles is 
determined using a simple absorbance assay at 510nm, based on solutions 
containing known quantities of iron. Solutions at different concentrations (0, 5, 25, 
50, 75, and 100 ppm) are prepared by dilution in water for MR. The solutions are 
stored in plastic cryogenic vials, and the amount of air in each vial is minimized to 
eliminate signal interference from the air-water interface. All vials are embedded 
into Styrofoam for MR measurements.  
 
MR Equipment & Experiments 
Four MR experiments were performed for each set of samples. Two experiments 
were designed to measure R2, one was designed to measure R2*, and one was 
designed to measure R1. All experiments were performed on a 3 Tesla GE HDx 
clinical MR imager (GE, Milwaukee, WI) equipped with 40 mT/m gradients capable 
of 150 mT/m/sec slew rate and an 8 channel brain phased array receiver coil for 
signal reception.  
The first experiment, designed to measure R2, used a two-dimensional single echo 
spin echo sequence with a repetition time (TR) of 2 sec and repeated 
independently for 11 echo times (TE) ranging from 9 ms to 125 ms (TEi =9, 14, 20, 
26, 34, 42, 50, 65, 80, 102.5 and 125 ms). Other sequence parameters were 2 mm 
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slice thickness, 13-15 cm field-of-view (FOV), 256256 matrix, 2 signal averages 
and 19 kHz bandwidth. With these parameters, typical signal-to-noise ratio (SNR) 
was 40 at the shortest TE, reducing to 10 no earlier than the fourth echo for the 
highest agent concentrations.  
Because T2 measurements using this Hahn single echo spin echo sequence are 
sensitive to molecular diffusion, a second experiment was performed to measure 
R2 using a three-dimensional multi-echo spin echo Carr-Purcell-Meiboom-Gill 
sequence.139–143 This sequence utilized non-selective radiofrequency pulses with 
composite refocusing (90x-180y-90x) as well as gradient crushers that alternated in 
polarity in every echo and that diminished in amplitude at every pair of echoes.144 
Sequence parameters were 1.5 sec TR, 16 echoes evenly spaced at 7.4 ms (first 
echo at 7.4 ms, last echo at 118.4 ms), 2 mm slice thickness, 13-15 cm FOV, 96 
(readout)  72 (phase)  38 (slice) matrix, 1 signal average, and 32.8 kHz 
bandwidth. SNR was typically >100 at the first echo, and reducing to no less than 
30 at the 4th echo for the highest agent concentration.  
R1 was measured using a two-dimensional single echo spin echo sequence but 
with a fixed echo time of 9 ms and independently repeated for 12 repetition times 
ranging from 100 ms to 9 sec (TRi=100, 250, 500, 750, 1000, 1366, 1750, 2500, 
4000, 5500, 7000, and 9000 ms). Other parameters were identical to the single 
echo spin echo R2 experiment except that 4 signal averages were used for the 
shorter TRs in order to increase SNR, except for acquisitions with TR >2.5 sec for 
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which only 1 signal average was used to maintain a reasonable scan time. With 
these parameters, SNR was between 10–30 for the three shortest TRs and >30 
for the remaining TRs. 
Finally R2* was measured using a two-dimensional multi echo gradient recalled 
echo sequence with a 1.5 sec TR and 8 echoes collected between 3.6 and 40 ms 
with a spacing of 5.3 ms. Other sequence parameters were 2 mm slice thickness, 
13–15 cm FOV,256  256 matrix, 2 signal averages and 32.8 kHz bandwidth. 
SNR was 12 at the first echo and dropped to approximately 3 by the 4th echo at 
the highest agent concentration. 
 
MR Analysis 
Analysis of MR signal intensities to determine sample relaxation rates was 
performed using custom software developed in MATLAB (version R2013b, 
Mathworks Inc., Waltham MA). The software performed non-linear non-negative 
least squares fitting of signal intensity measurements across either the echo (for 
T2, T2*) or the repetition times (for T1), using idealized mono-exponential signal 
models. For T2 and T2* measurements, the signal model was 𝑠(𝑇𝐸𝑖) = 𝑠𝑇𝐸=0𝑒
−𝑇𝐸𝑖𝑅, 
where R the corresponding R2 or R2* relaxation rate. For T1 measurements, the 
signal model was 𝑠(𝑇𝑅𝑖) = 𝑠𝑇𝑅=∞(1 − 𝑒
−𝑇𝑅𝑖𝑅1) . In both models, the non-linear 




Signal intensities in each sample were measured using a custom software user 
interface (also developed in MATLAB). The software allowed all DICOM images 
corresponding to a single experiment (e.g., all spin echo acquisitions with a single 
TR and varying TE for a T2 experiment) to be loaded, and regions-of-interest (ROIs) 
to be placed in any source axial slice in the image volume of one acquisition. The 
software then propagated the ROI to the corresponding slice and location in every 
acquisition (e.g., the multiple TEs or multiple TRs) in the experiment, thereby 
producing the average signal measurement for that ROI across the corresponding 
independent variable. ROIs were placed at the center of each vial for each solution 
concentration in at least 4 different axial slices covering the vial. The fitted 
relaxation times were recorded into Excel and averaged over the multitude of ROIs 
collected for each vial.  A least squares linear fit was finally used to calculate the 
agent relaxivity (r1, r2, r2*) as the slope of a straight line corresponding to the 
measured relaxation rates (R1, R2, R2*) vs. known iron concentration values of each 
vial. Standard error in the slope was also estimated from this output. Plotting of all 





Altering the number of peptides or the peptide ratio per SPION 
SPIONs with different quantities of attached peptide (HABP and OPN) were 
fabricated by stoichiometrically altering the quantities of peptide added to the 
SPION solutions before incubation. After addition of the correct amounts of peptide 
to target the addition of 5, 10, 25, 50, and 100 peptides per SPION for both HABP- 
and OPN-SPIONs, aggregation of the 100 peptide per SPION samples was 
observed for HABP-SPIONs. The aggregated SPIONs were not further tested 
(Figure 3.1).   
 
Figure 3.1: Assessment of the impact of functionalizing SPIONs with different quantities 
of peptides per SPION. Peptides per SPION are estimated based on the peptide addition 
reaction stoichiometry. Studies were performed using both (A) HABP-SPIONs and (B) 
OPN-SPIONS. 100 peptides per SPION HABP-SPIONs were not tested for binding 
properties because they are unstable in solution upon fabrication. Error bars are standard 




Across the different samples tested, the number of peptides per SPION did not 
appear to have a large effect on the percent of SPIONS that bind to a given quantity 
of HA. For HABP-SPIONs, increasing the number of peptides per SPION generally 
yielded an increased percent bound for a given quantity of HA; however, these 
differences are quantitatively small. The differences are only statistically significant 
in comparing HABP-SPIONs with 5 peptides/SPION to those with 50 
peptides/SPION. For OPN-SPIONs, on the other hand, increasing the number of 
peptides per SPION generally yielded a decreased percent bound for a given 
quantity of HA. These differences are also qualitatively small. Again, the 
differences are only statistically significant in comparing OPN-SPIONs with 5 
peptides/SPION to those with 50 peptides/SPION.   
SPIONs with different ratios of attached peptide (HABP:OPN) were also fabricated 
by stoichiometrically altering the quantities of peptides added to the SPION 
solutions before incubation. All peptide solutions were mixed separately before 
adding this solution to the SPIONs. After addition of the correct amounts of peptide 
to target the addition 25 peptides per SPION with ratios of 1:1, 1:2, and 2:1 




Figure 3.2: Assessment of impact of functionalizing SPIONs with different peptides ratios 
between HABP and OPN on a given SPION. Peptides per SPION are estimated based on 
the peptide addition reaction stoichiometry. Error bars are standard deviation; n= 3. 
 
Across the different samples tested, the ratio of different peptides on each SPION 
did not appear to have a large effect on the percent of SPIONS that bind to a given 
quantity of HA. Differences between samples were not significant.  
  
PEGylation of non-targeted SPIONs 
It was hypothesized that altering the chemical and physical properties of the 
SPIONs would yield alterations in the MR properties, and that these 
measurements could be used to identify a specific SPION makeup that would yield 
an optimal MR signal. In order to optimize the MR signal of SPIONs, both 4nm and 
10nm SPION cores were successfully functionalized using 3 different fabrication 
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schemes, as shown in Figure 3.3. As described above, methods of fabrication 
included: (1) direct PEGylation via ligand exchange with PO-PEG, (2) a ligand 
exchange to coat particles with citric acid, followed by covalent addition of NH2-
PEG via EDC/NHS chemistry, and (3) PEGylation via hydrophobic interactions 
between oleic acid on the SPION surface and DSPE residues on DSPE-PEG. For 
each method of fabrication, at least 3 different PEG chain lengths were added to 
different particle samples to observe the effect of polymer chain length on the 
resulting MR relaxivities. Tested PEG chain lengths were: (1) for PO-PEG SPIONs 
– 1000, 2000, and 5000 Da, (2) for NH2-PEG SPIONs – 1000, 2000, 3400, and 
5000 Da, and (3) for DSPE-PEG SPIONs – 1000, 2000, 5000 Da. In total, 20 
unique SPIONs were fabricated, characterized, and tested. 
 
Figure 3.3: Schematic of 
particle fabrication. Oleic 
acid particles are coated 
with PEG via one of three 
methods: (1) direct 
PEGylation via ligand 
exchange with PO-PEG, 
(2) a ligand exchange to 
coat particles with citric 
acid, followed by covalent 
addition of NH2-PEG via 
EDC/NHS chemistry, or 
(3) PEGylation via 
hydrophobic association 
between oleic acid and 




Dynamic Light Scattering, Zeta Potential, and Thermogravimetric Analysis 
DLS, zeta potential measurements, and TGA were used to characterize and 
confirm the success of SPION fabrication for each type of SPION produced (Table 
3.1). Notably, each method of fabrication produced SPIONs with different 
properties in terms of effective diameter, zeta potential, and, in some cases, 
surface density. In PO-PEG SPIONs, nanoparticle effective diameter appears to 
increase as PEG chain length increases (e.g. for 4nm and 10nm PO-PEG SPIONs), 
as expected. These differences however were not statistically significant across 
multiple batches (p > 0.05). For DSPE-PEG SPIONs (both 4 and 10nm diameter), 
the 5k PEG samples had a smaller effective diameter than either the 1k or the 2k 
PEG, although again these differences were not significant (p > 0.05). This trend 
was also observed for 4nm NH2-PEG SPIONs, with 3.4k NH2-PEG SPIONs being 
significantly larger (p < 0.05) than 1k, 2k, and 5k NH2-PEG SPIONs. For 10nm 
NH2-PEG SPIONs, this did not appear to be the case; 5k NH2-PEG SPIONs were 
significantly larger than 1k, 2k, and 3.4k NH2-PEG SPIONs. For both PO-PEG and 
NH2-PEG SPIONs, the effective diameters of the 4nm samples were significantly 
smaller (p < 0.05) than the equivalent 10nm samples. For DSPE-PEG SPIONs, 
this was not the case. Finally, it can be observed for all samples that for a given 
core size and PEG chain length, the effective diameter observed between different 
PEGylation methods was such that NH2-PEG SPIONs < PO-PEG SPIONs < 
DSPE-PEG SPIONs. These differences vary in statistical significance, but this 




















1000 18.66  4.14 -14.75  1.58 0.56  0.06 
2000 22.67  3.21 -5.63  6.13 0.82  0.09 
5000 22.86  2.54 -1.62  4.21 0.93  0.23 
NH2-PEG 
(Method 2) 
1000 14.79  3.74 -19.46  1.71 0.68  0.13 
2000 18.04  4.24 -15.89  1.11 0.93  0.04 
3400 38.46  6.16 -10.85  1.29 0.87  0.06 
5000 20.03  4.42 -8.93  1.21 0.86  0.15 
DSPE-PEG 
(Method 3) 
1000 64.24  16.19 -23.55  13.85 0.70  0.05 
2000 82.40  26.49 -18.36  23.57 0.82  0.05 




1000 40.69  5.42 -6.30  1.29 0.41  0.10 
2000 42.71  7.45 -13.35  3.16 0.67  0.13 
5000 45.93  5.47 -8.94  0.89 0.66  0.18 
NH2-PEG 
(Method 2) 
1000 30.22  5.46 -22.79  2.75 0.35  0.31 
2000 27.33  5.17 -13.79  1.84 0.62  0.08 
3400 31.12  5.57 -20.67  1.39 0.67  0.03 
5000 41.21  6.35 -13.54  1.65 0.60  0.14 
DSPE-PEG 
(Method 3) 
1000 58.07  15.21 -31.14  31.40 0.69  0.00 
2000 75.45  28.67 -16.10  33.98 0.69  0.01 
5000 55.49  11.70 -3.61  16.48 0.77  0.27 
 
Table 3.1: Summary of DLS, zeta potetial, and TGA data for all particles produced as part 
of testing different PEGylation methods, PEG chain lengths, and SPION diameters for 
their impact to MR signal. Effective diameter was measured using DLS, zeta potential was 
measured on the same machine, and surface density was calculated from TGA results. 
Results are represented as mean  standard deviation , n = 3.  
 
Zeta potential results also reflected interesting trends. Generally speaking, zeta 
potential decreased with increasing PEG chain length (for 4nm PO-PEG SPIONs, 
4nm NH2-PEG SPIONs, and 10nm DSPE-PEG SPIONs). For 4nm DSPE-PEG 
SPIONs, zeta potential results showed high error and no observable trend. For 
10nm PO-PEG SPIONs, zeta potential results showed low error, but again, no 
definitive trend. And for 10nm NH2-PEG SPIONs, zeta potential appeared to be 
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bimodal, with 1k and 3.4k samples having more similar zeta potentials, which were 
different than the similar zeta potentials shared by 2k and 5k samples. Given the 
same PEG chain length and PEGylation method, the zeta potentials for 4nm 
samples were generally higher (or, closer to neutral) than the zeta potential for the 
equivalent 10nm sample. And finally, a definitive trend in zeta potentials as a 
function of PEGylation method was not observed. 
TGA results generally indicated averages similar to the targeted surface density of 
0.7 PEG chains/nm2. Importantly for the comparability of these results to one 
another, there were no statistically significant differences (p > 0.05) in surface 
density between particles within the same PEGylation method and core size (e.g. 
all 10nm PO-PEG SPIONs) – with the exception of 4nm DSPE-PEG 5k samples, 
which exhibited a significantly higher surface density than either 1k or 2k DSPE-
PEG samples of the same core size (p < 0.05). This means that MR results from 
each given PEGylation method and core size are solely due to differences in PEG 
chain length, with the exception of results from the 4nm DSPE-PEG 5k samples 
(c.f., MR results below). Additionally, there were no statistically significant 
differences in surface density between particles with the same PEG chain length 
and core size (e.g. all 4nm SPIONs with any 1k PEG). This means that MR results 
from each given core size and PEG chain length are solely due to differences in 




MR Equipment & Experiments 
The impact of SPION core size, PEGylation method, and PEG chain length on r1 
relaxivity was marked (Figure 3.4). The PEGylation method and the resulting 
chemical composition of the layer closest to the SPION core had a large impact on 
agent r1 rate. DSPE-PEG SPIONS had a markedly lower r1 relaxivity than either 
NH2-PEG or PO-PEG SPIONs. For 4nm SPIONs with comparable PEG chain 
lengths, NH2-PEG SPIONs had r1 relaxivities at least 2.15x higher than PO-PEG 
SPIONs, and at least 8.23x higher than DSPE-PEG SPIONs for equivalent PEG 
chain lengths. For 10nm SPIONs, NH2-PEG SPIONs had r1 relaxivities of at least 
2.09x higher than PO-PEG SPIONs, and at least 33.87x higher than DSPE-PEG 
SPIONs. 
Interestingly, for NH2- and PO-PEG SPIONs, the maximum effect imparted on r1 
relaxivity by changing the PEG chain length was between 34-45% and was not 
markedly different for the two different core sizes. However, for DSPE-PEG 
SPIONs, r1 relaxivity differed by a factor of 360 (10 nm core) to 480% (4 nm core) 




Figure 3.4: Impact of SPION core size and PEG chain length on r1 for PO-PEG SPIONs, 
NH2-PEG SPIONs, and DSPE-PEG SPIONs. Error bars are standard error in the 
calculated slope value.  
 
For 10nm SPIONs, increasing the PEG chain length generally resulted in an 
increase in r1 relaxivity (Figure 2). For 4nm SPIONs, a trend was not apparent. 
With the notable exception of the 5k PO-PEG SPIONs for which the 10nm SPION 
had a higher r1 relaxivity, for all PEGylation methods and PEG chain lengths, 4nm 
SPIONs had higher r1 relaxivities than their 10nm counterparts. This is the opposite 
effect than expected (and previously reported) for r2 relaxivity. Differences in 
equivalent samples with different core sizes ranged from 0.91x (PO-PEG5k, where 




The impact of SPION core size, PEGylation method, and PEG chain length on r2, 
as measured using the CPMG method, was significant, and only partly in line with 
what was observed with the r1 trends (Figure 3.5). Again, the PEGylation method 
and the resulting chemical composition of the layer closest to the SPION core had 
the most definitive impact on r2 relaxivities. In line with r1 results, across PEG chain 
lengths, NH2-PEG SPIONs had the highest r2 relaxivities; 1.41 – 4.67x higher than 
DSPE-PEG SPIONs and 1.06 – 7.02x higher than PO-PEG SPIONs. 
 
Figure 3.5: Impact of SPION core size and PEG chain length on r2 CPMG for PO-PEG 
SPIONs, NH2-PEG SPIONs, and DSPE-PEG SPIONs. Error bars are standard error in 
the calculated slope value.  
 
For NH2-PEG SPIONs with both 4nm and 10nm cores, increasing the PEG chain 
length lead to an increase in r2 relaxivity. This was also the case only for DPSE-
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PEG SPIONs with 10nm cores. For DSPE-PEG SPIONs with 4nm cores the 
largest PEG length also led to the largest r2, but there was a drop in r2 at the 
intermediate PEG length. For PO-PEG SPIONs with 10nm cores, there was not a 
definitive trend. However, for PO-PEG SPIONs with 4nm cores, increasing the 
PEG chain length lead to a consistent decrease in r2 relaxivity. Additionally, for 
NH2-PEG SPIONs, r2 relaxivities were higher for the 10nm core sizes at each PEG 
chain length. Differences in equivalent samples with different core sizes ranged 
from 1.02x (PEG5k) to 1.30x (PEG2k). However, the opposite was true for PO-
PEG SPIONs. Differences in equivalent samples with different core sizes for PO-
PEG SPIONs ranged from 1.57x (PEG2k) to 3.56x (PEG1k). Differences in 
equivalent samples with different core sizes for DSPE-PEG SPIONs did not show 
a consistent trend.  
Spin echo-derived r2 relaxivities were higher than or comparable to (i.e. the 
calculated values share an overlapping standard error range) CPMG relaxivities 
as expected (Figure 3.6). Where they were greater, r2 SE-derived relaxivities were 
1.023x to 1.20x the r2 CPMG-derived relaxivities, with the highest ratio observed 




Figure 3.6: Comparison between relaxivities derived from SE measurements (blue) and 
CPMG measurements (orange). The general similarity of these results indicates that 
diffusion of particles in solution did not play a substantial role in altering measured 
relaxation rates. As with other experiments, 3.4k PEG samples were only tested in NH2-
PEG SPIONs due to limited PEG agent availability. Error bars are standard error in the 
calculated slope value. 
 
 
The r2* relaxivities are provided in Figure 3.7. The impact of SPION core size, 
PEGylation method, and PEG chain length on r2* was significant. With the 
exception of the 4nm 1k PO-PEG SPIONs, NH2-PEG SPIONs had the highest r2* 
relaxivities across PEG chain lengths. For NH2-PEG SPIONs with both 4nm and 
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10nm cores, increasing the PEG chain length lead to an increase in r2* relaxivity. 
This was also the case only for DPSE-PEG SPIONs with 10nm cores. For DSPE-
PEG SPIONs with 4nm cores, and for PO-PEG SPIONs with 10nm cores, there 
was not a definitive trend. However, for PO-PEG SPIONs with 4nm cores, 
increasing the PEG chain length lead to a consistent decrease in r2* relaxivity. 
Additionally, for NH2-PEG SPIONs, r2* relaxivities were higher for the 10nm core 
sizes at each PEG chain length, while the opposite was true for PO-PEG SPIONs. 
Differences in equivalent samples with different core sizes for DSPE-PEG SPIONs 
did not show a consistent trend.  
 
Figure 3.7: Impact of SPION core size and PEG chain length on r2* for PO-PEG 
SPIONs, NH2-PEG SPIONs, and DSPE-PEG SPIONs. Error bars are standard error in 




The r2* relaxivities are plotted vs. r2 relaxivities for each given sample in Figure 
3.8. As expected, they were either comparable to (with the inclusion of standard 
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error) or significantly greater than CPMG relaxivities. Where they were greater, r2* 
were 1.08x to 2.67x the r2 CPMG-derived relaxivities, with the highest ratio 
observed for 1k PO-PEG, 4nm SPIONs. This particular data point was deemed an 
outlier and excluded from further analysis. Linear regressions were performed on 
these data not including the outlier, and are indicated with the black lines in Figure 
3.8. Grey shading indicates the 95% confidence interval. It can be observed that 
there is a strong positive correlation between r2* and r2 for each PEG attachment 
method (all R > 0.85). For NH2-PEG SPIONs, the relationship between r2* and r2 
is almost perfectly linear (R = 0.986). The slopes of the linear regression also vary 
with PEG attachment method: 0.69 ± 0.16 for DSPE-PEG SPIONS, 1.13 ± 0.07 for 
NH2-PEG SPIONs, and 1.35 ± 0.24 for PO-PEG SPIONs (mean ± standard error) 
While the NH2-PEG SPIONs and PO-PEG SPIONs are comparable, given the 
overlapping standard errors, the relaxivities of the DSPE-PEG SPIONs have a 
significantly different relationship.   
 
Figure 3.8: Relationship between r2* and CPMG-derived r2 values across all samples. 





Because HA deposits in early CAVD are generally present in very small quantities, 
it is desirable and necessary to synthesize SPIONs with substantial signal 
enhancement. This will ultimately help to improve the sensitivity of diagnosis, and 
enable the detection of earlier disease in patients. As discussed in the introduction 
to this chapter, SPION signal enhancement can be achieved via one of two 
methods: 1) optimizing targeted SPION binding to HA, to ensure that as many 
SPIONs as possible can bind to the target, and/or 2) optimizing the targeted 
SPION makeup to enhance MR signal of the particles themselves.  
For approach 1 (optimizing targeted SPION binding to HA to ensure that as many 
SPIONs as possible will bind to the target), different peptide quantities per SPION 
were tested to better understand whether or not altering the density of the peptide 
coating could improve the binding properties of the SPIONs. It was largely 
observed that altering either the number of peptides per SPION or the composition 
of the peptide coating in terms of HABP:OPN ratio did not yield large quantitative 
differences in particles binding to a given quantity of HA. This is perhaps 
unsurprising, especially as these studies were not performed under flow conditions. 
While it may be helpful for more peptides on each SPION to bind to HA, these 
differences may not be measurable under the conditions used for these 
experiments. Future work may be performed to observe differences in the binding 
properties of SPIONs with different quantities of attached peptide under flow, 
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where the number of peptides per SPION that successfully bind to the HA may 
have more of an impact. However, as the only significant differences observed in 
these studies were between samples with 5 peptides/SPION and 50 
peptides/SPION, and as neither set of samples showed significant differences from 
samples with 25 peptides/SPION, 25 peptides/SPION was chosen as the baseline 
value for both HABP- and OPN-SPIONs moving forward. However, it should be 
noted here that, as SPIONs with 10 peptides/SPION yielded statistically similar 
results for both HABP- and OPN-SPIONs, these could be used instead for future 
studies if cost-effectiveness of SPION production is of concern. 
Additionally, to fully explore options for approach 1, SPIONs with different ratios of 
HABP:OPN combined onto a single SPION were tested. It was hypothesized that, 
given the slightly different properties of HABP- and OPN-SPIONs at low 
concentrations of HA (Figure 2.4), this approach might serve to combine the 
properties of both HABP- and OPN-SPIONs in a quantifiable manner. These, 
similarly, did not yield significant differences in terms of the binding properties of 
the SPIONs. As there was no measurable difference in SPION binding properties 
when both HABP- and OPN-peptides were used in comparison to when only one 
peptide was used, HABP- and OPN-SPIONS were produced separately for the 
remainder of the studies described in this dissertation. This was done because 
HABP and OPN peptides are two of the most expensive reagents in the SPION 
production process; these results indicate that purchasing both peptides and 




For approach 2 (optimizing the targeted SPION makeup to enhance MR signal of 
the particles themselves), as previously discussed, 20 different SPION samples 
were produced with different core sizes, PEG chain lengths, and PEGylation 
methods. 
SPION core sizes of 10 and 4nm were chosen to reflect those sizes that are often 
developed for MR applications in the literature.38,113,145 SPIONs are often grouped 
into three categories based on size: (1) standard SPIONs (50–180nm), (2) 
ultrasmall SPIONs (10–50nm), and (3) very small SPIONs (<10nm).114 The core 
sizes selected allow us to examine both ultrasmall and very small SPIONs, which 
are indeed the most commonly encountered.  
The three PEGylation methods selected represent a cross section of different 
PEGylation methods widely used in the literature, and were chosen based on the 
chemical properties they would impart to the nanoparticles. It was hypothesized 
that the hydrophilicity or hydrophobicity of the chemical group closest to the SPION 
core would have a large impact on the MR relaxivities, as this is largely dependent 
on the ability of water to move around and close to the SPION cores.  
Method 1 (PO-PEG) is similar to many direct PEGylation or direct ligand exchange 
methods, where the SPION cores are PEGylated in a one-step process that relies 
on direct interaction between a functional group on the PEG and the SPION 
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core.137 This particular method will result in SPIONs with a small, combination 
hydrophilic/hydrophobic group closest to the core; PO-PEG dissolves readily in a 
combination of ethanol and n-hexane. Method 2 (NH2-PEG) is similar to many two-
step processes, where a ligand exchange is performed to first replace the original 
(often hydrophobic) coating of the SPIONs, followed by PEGylation via attachment 
to the new coating material.97,98 This particular method will result in SPIONs with 
a small, strongly hydrophilic group closest to the core. Method 3 (DSPE-PEG) is 
similar to many one-step processes that rely upon somewhat weaker hydrophobic 
interactions or associations to link the PEG to the SPION core.135 This particular 
method will result in SPIONs with a bulky, very hydrophobic group closest to the 
core. 
The PEG chain lengths (1000, 2000, (3400), and 5000 Da) were selected because 
they tend to be widely commercially available, and have been widely used in 
previous reports dealing with functionalized SPIONs.97,98,135,137 The targeted PEG 
chain density on the SPIONs (0.7 PEG chains/nm2) was selected as a fairly high 
target; this target should be close to the maximum of what is feasible in a well-
equipped laboratory setting.146 
DLS measurements were chosen to observe effective rather than absolute 
diameters as the behavior of particles in solution was of particular interest for this 
study. Effective diameters were measured in DI water, so any contribution of ions 
should be negligible; however, differences in the amount of aggregation or the 
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spread of the PEG layer should be reflected in differences in the measured 
effective diameter. Because both aggregation as well as PEG chain conformation 
may impact measured MR relaxivities, effective diameter measurements were of 
more use than absolute diameter as measured by methods such as, e.g., 
transmission electron microscopy (TEM). In this series of measurements, 
variations between samples fabricated with different parameters were observed.  
It would generally be expected that, with equivalent core sizes and PEGylation 
methods, longer PEG chain lengths would lead to larger effective diameters, as 
observed with PO-PEG SPIONs. However, in cases where this was not observed, 
it is possible that aggregation effects were at play; for example, DSPE-PEG 
SPIONs with smaller PEG chain lengths may aggregate more readily, and thus 
only the effective diameter measured for the 5k DSPE-PEG SPIONs measured the 
effective diameter of single SPIONs, rather than multiple particles. This seems to 
be a likely explanation particularly for DSPE-PEG SPIONs, as the effective 
diameter of 5k DSPE-PEG SPIONs was generally substantially lower than the 2k 
DSPE-PEG SPIONs of the same core size. The larger standard deviation 
observed in DSPE-PEG SPION effective diameter measures could also be 
reflective of aggregation. For NH2-PEG SPIONs, where the general size 
progression is 1k < 2k < 5k < 3.4k, it is thought that the observed difference 
between 3.4k and 5k samples may be due to a difference in the preferred PEG 
chain conformation, or to potentially a small amount of aggregation occurring, as 
the standard deviations are not as high as those observed for DSPE-PEG SPIONs.  
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In comparing samples with similar PEGylation methods and PEG chain lengths, it 
would be expected that the effective diameter of 4nm samples would be smaller 
than 10nm samples. This was confirmed for both PO-PEG and NH2-PEG SPIONs. 
However, this was not true for DSPE-PEG SPIONS. It is likely that, again, 
aggregation plays a role in these results, and that perhaps DSPE-PEG SPIONs 
are less stable in aqueous solution than samples where there is a more hydrophilic 
group present closer to the core. 
Zeta potential measurements reflect the potential at the slipping/shear plane of 
particles in solution.147 While PEG itself does not carry a high surface charge, 
SPIONs alone in solution tend to carry a high negative charge (e.g. CA-SPIONs 
have a zeta potential of around -35mV; the zeta potential of OA-SPIONs in water 
cannot be measured, as OA-SPIONs are insoluble in water). It is thus expected 
that coating with the more neutral PEG will raise the zeta potential of the particles 
closer to neutral (0mV).147,148 This was observed in all cases.  
The general increase towards neutral of zeta potential with increasing PEG chain 
length may perhaps be expected; it is possible that longer PEG chains help to 
better “mask” the highly negatively charged SPION core. Additionally, the higher 
zeta potential in the 4nm samples as compared to the 10nm samples of the same 
PEGylation method and PEG chain length may be due to the same effect; the PEG 
chains are simply larger with respect to the size of the SPION core, and may thus 
do a better job of masking the negative charge of the core. Finally, it is intuitively 
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understood that there was no observed trend in zeta potentials as a function of 
PEGylation method, since the solution-facing ends of each PEG chain should have 
been chemically identical regardless of the PEGylation method. 
The observed results from TGA tests simply indicated that the majority of samples 
have non-significant differences in terms of surface coverage (with the exception 
of 4nm DSPE-PEG 5k samples, which have a statistically significantly greater 
surface coverage). This indicates that, with the exception of the 4nm DSPE-PEG 
5k SPIONs, observed differences in MR relaxivities between samples will solely 
be due to differences in core size, PEG chain length, or PEGylation method. This 
is an important confirmation step that has been omitted in previous literature 
examining the impact of these parameters on SPION MR properties.98,135 
Perhaps the most salient trend in MR measurements is that r1 and r2 relaxivities 
are greater in NH2-PEG SPIONS than either PO-PEG or DSPE-PEG SPIONs of 
the same core size and PEG chain length. It is hypothesized that this is due to the 
hydrophilic nature of the group closest to the core for these SPIONs (citric acid), 
in comparison to the less hydrophilic nature of the phosphine oxide and the 
hydrophobic nature of the DSPE. The more hydrophilic group near the core may 
allow water to move more easily closer to the core, and spend more time in 
proximity to the magnetic field generated by the core. In comparing PO-PEG and 
DSPE-PEG SPIONs across particles with the same core size and PEG chain 
length, results appear to differ between r1 and r2 relaxivities. PO-PEG SPIONs 
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show far higher r1 relaxivities across the board. However, the difference between 
r2 relaxivities for PO-PEG and DSPE-PEG SPIONs do not show a consistent trend. 
As expected, r2* relaxivities were either comparable to, or greater than, CPMG-
derived r2 relaxivities. 
For NH2-PEG and DSPE-PEG SPIONs, within a given SPION core, increasing the 
PEG chain length from 1k to 5k generally lead to an increase in for r1 and CPMG-
derived r2 relaxivities. This is in keeping with results from Tong, et al. who 
considered PEG chain lengths over 1kDa.135 This is likely because the increased 
PEG chain length creates a larger corona which slows the movement of water 
molecules around the particle, thus increasing the amount of time the water 
protons spend in proximity to the core. Interestingly, this is not true for PO-PEG 
SPIONs, which do not show a consistent trend with PEG chain length. While for 
4nm PO-PEG SPIONs, increased PEG chain length leads to decreased r2, this 
does not hold true for 10nm PO-PEG SPIONs.  
The trend observed with respect to the r2 vs. r2* data is likely because the coating 
of the particles has an impact on the magnetic field. The particles with more 
hydrophilic coatings (NH2-PEG SPIONs and PO-PEG SPIONs) showed similar 
relationships between r2 and r2*, while DSPE-PEG SPIONs showed a substantially 
lower slope in the regression. This may mean that the hydrophilicity or 
hydrophobicity of the group closest to the core has an effect on the magnetic field.  
Results of this study do not necessarily corroborate some previous findings,131,132 
for example that SPIONs with larger core sizes yield higher r2 relaxivities in 
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samples with equivalent PEG chain length and PEGylation method. Although this 
is true for NH2–PEG SPIONs, there is a less distinctive trend for both PO-PEG and 
DSPE-PEG SPIONs. The trend observed in 5kDa PO-PEG SPIONs could 
potentially be linked to the increased surface coverage of the 4nm samples as 
measured by TGA; however, this is not the case in the 1kDa samples. On the other 
hand, SPIONs with larger core sizes generally yielded lower (or comparable) R1 
relaxivities in samples with equivalent PEG chain length and PEGylation method. 
This trend may be related to recent results demonstrating that SPIONs with 
sufficiently small core diameters can actually be used as T1 contrast agents.137,149 
Additional work will need to be performed to further elucidate the impact of SPION 
core size on MR relaxivities with different PEG attachment methods. 
Although other direct relationships between relaxivities and the other measured 
parameters were examined, there were largely no significant correlations (data not 
shown). In the future, it may be beneficial to perform multiparametric modeling on 
these or similar results to observe the combined impact of multiple factors.  
Overall, results from these studies indicate that the chemical composition and, in 
particular, the hydrophobicity/hydrophilicity of the group that serves to link PEG 
chains to a SPION core may actually play a larger role in the resulting MR signal 
than other variable properties such as SPION core size and PEG chain length. In 
addition, these studies show that the impact of SPION core size and PEG chain 
length on the resulting sample relaxivities is not a simple relationship, but appears 
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to be conflated as well with the impact of the PEGylation method and the nature of 
the chemical group closer to the SPION core. To our knowledge, this is the first 
time a study has been performed examining the impact of PEGylation method on 
MR signal; it is also the first time such a comprehensive and controlled study of 




Chapter 4: Characterization of the Medical Properties of Targeted SPIONs 
4.1 Introduction 
Previous work described in Chapters 2 and 3 detailed the fabrication, in vitro 
characterization, and MR signal optimization of HA-targeted SPIONs. In this 
chapter, we focus on the medically-relevant properties for the eventual successful 
clinical use of these targeted SPIONs.  
In the clinic, HA-targeted SPIONs intended for use in the detection of early-stage 
CAVD would be administered to patients, potentially intravenously, and would be 
expected to bind to any HA deposits present in the aortic valve. They may 
additionally demonstrate off-target binding to HA present elsewhere in the body. 
The final, fully-functionalized and bound SPIONs must therefore be detectable via 
standard MR imaging; they must not cause harmful systemic or local effects; and 
they must be able to reach their target and bind successfully. The experiments 
described in this chapter aim to show that the HA-targeted SPIONs fabricated in 
Chapter 2 and optimized in Chapter 3 have all of these properties, and are thus 
suitable for further testing development. 
Although the MR signal of PEGylated SPIONs was measured and optimized as 
discussed in Chapter 3, these results do not account for the potential impact of the 
addition of a targeting peptide on the MR signal. Previous results in the literature 
have only occasionally addressed the fact that the addition of any targeting moiety 
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such as a peptide will alter the MR signal of SPIONs.150,151 The study by Faraj, et 
al. indicates that the addition of an antibody in their system typically led to an 
increase in R2 and no alteration in R1, though the increase was inconsistent 
between samples.151 Many studies simply perform MR measurements with the 
final, fully-conjugated SPIONs.152–154 Measuring the change in MR signal as a 
result of peptide addition can aid in understanding what may be expected in 
measurements made in a clinical setting.  
An additional, crucial pre-clinical MR study entails measuring the MR signal of 
SPIONs bound to HA in vitro. Previous results in the literature have reported that 
bound SPIONs generally demonstrate an increased MR signal compared to 
unbound SPIONs.155,156 This is thought to be because particles bound to their 
target will move more slowly through solution, and thus moving water molecules in 
the solution will spend more time in proximity to the core, leading ultimately to an 
increased MR signal. Although we have already demonstrated SPION binding to 
HA in vitro, observing binding via an alteration in MR signal is an additional, 
orthogonal method that can be used to confirm that binding is occurring. MR 
measurement of the fully-functionalized particles and confirmation of binding via 
MR are important benchmarks for ensuring particle functionality in a clinical setting.  
The potential for harmful systemic effects of HA-targeted SPIONs also must also 
be addressed. Unlike gadolinium contrast agents, SPIONs generally display low 
cytotoxicity, particularly for PEG-coated particles at relevant concentrations under 
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100 µg/mL.157–159 As others have reported, doses in humans have been ~1mg 
Fe/kg, corresponding to far less than 100 µg/mL (~13 µg/mL for an average adult 
male in the United States).160 Although transient systemic effects (e.g. diarrhea, 
nausea, headache) have been observed in vivo in some studies, these effects 
were reversible and diminished over time.51,161,162  Hypersensitivity/anaphylaxis 
reactions have been reported in the FDA-approved, carbohydrate-coated iron 
oxide agent Feraheme,51 indicating that further clinical evaluation of any potential 
iron-oxide based contrast agent would be of the utmost importance. Subsequent 
to injection, particles with diameters <60nm showed circulation times of ~90 
minutes, and tended to accumulate in the liver (80-90%) and the spleen (5-8%), 
with smaller quantities present in the brain, heart, kidney, lung tissue, bone marrow, 
and lymph nodes.163,164 The overall lack of long-term negative effects from SPIONs 
is thought to be primarily because they are degraded and cleared from systemic 
circulation by endogenous iron metabolic pathways, including uptake by 
macrophages in the liver and spleen.161,163,165 Thus, the systemic effects of 
SPIONs are generally considered to be minimal, although many studies continue 
to evaluate SPION toxicity in specific cell cultures, with specific surface 
modifications, and with specific incubation times. In this chapter, we evaluate the 
specific toxicity of PEG-, HABP-, and OPN-SPIONs at a biologically relevant 




In addition to considerations of systemic or cellular toxicity, the impacts of 
functionalized SPIONs on HA nucleation and formation are unknown. OPN and 
related peptides have been shown in literature to contribute to slowing the 
nucleation and formation of HA nanocrystals, in addition to potentially disrupting 
existing crystal structures.73,120 Although from the standpoint of CAVD, this effect 
may be beneficial and lend the functionalized SPIONs theranostic capabilities, this 
could present clinical issues systemically. HA nucleation and formation in the body 
is an active and ongoing process, not only where diseases such as CAVD are 
present, but also in maintenance of the skeletal system.166 Therefore, although 
preventing or disrupting HA deposition may help to treat CAVD by preventing 
further deposition of HA in the aortic valve, ultimately, the potential for negative 
systemic effects also must be explored. Previous studies such as those by de 
Bruyn et al. have examined HA nucleation and formation in vitro by using a 
borderline-saturated calcium-phosphate solution and examining the formation of 
HA nanocrystals over time using DLS.100 These studies tested the impact of adding 
various forms of the osteopontin protein (phosphorylated and non-phosphorylated) 
prior to mixing of the calcium and phosphate solutions, and determined that all 
tested forms of osteopontin do inhibit HA nucleation and formation. However, these 
studies were not performed in serum. Thus, in order to assess the impact of 
SPIONs on HA nucleation and formation, both HABP and OPN peptides and 
functionalized SPIONs were tested in a similar experimental setup, both without 
serum and in the presence of 50% serum.  
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Another important consideration in developing HA-targeted SPIONs for use as a 
CAVD diagnostic tool is the ability of the nanoparticles to reach their target in vivo. 
Small deposits of HA found in early stages of CAVD are contained within the valve 
structure; that is, they are subendothelial.167 Therefore, particles in the 
bloodstream must pass through the endothelial barrier to reach the HA deposits. 
Although previous studies by Kim et al. have demonstrated that nanoparticles of 
diameters <70nm are able to pass through the endothelial barrier under 
inflammatory conditions in atherosclerotic vessels,168 similar studies have not been 
performed in heart valves, which experience vastly different pressures and flow 
dynamics than vessel walls. For example, the aortic valve experiences direct 
pressure during diastole, while vessel walls typically experience shear stress 
(Figure 4.1A).57 To account for this, we used a unique Transwell and 
centrifugation setup that we developed and customized particularly for this 
application. Transwell experiments were performed to examine nanoparticle 
translocation through an endothelial cell layer under physiologically-relevant 




Figure 4.1:57 (A) Hemodynamic force perspective of systole and diastole in the aortic 
valve. (B) Graphic representation of the cellular and extracellular architecture of a normal 
aortic valve. (C) Representation of the genes involved in the osteogenic phenotype of a 
calcified aortic valve surface.  
 
Finally, although the studies described thus far have evaluated binding to HA under 
medically-relevant circumstances, binding to HA in diseased valve samples has 
not yet been evaluated. The microenvironment in the aortic valve will differ 
distinctly from the experimental setups described thus far in this dissertation. In 
addition to HA, amorphous calcium phosphate, and endothelial cells, the aortic 
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valve contains interstitial cells and extracellular matrix components including 
collagen, glycosaminoglycans, and elastin (Figure 4.1B). Assessing HA-SPION 
binding to HA deposits in the aortic valve can be performed either by examination 
of an animal model, or by using excised human aortic valve samples.  
Although there are several animal models of CAVD, to date no single animal model 
is fully characteristic of human CAVD.57 The most commonly used animal models 
are mouse, rabbit, and pig models. However, the mouse aortic valve structure 
differs significantly from that of humans,169 rabbits do not form spontaneous 
atherosclerotic lesions and differ from human in their lipid metabolism,170–175 and 
porcine models are often prohibitively expensive and difficult to maintain. To 
overcome these limitations, we have instead tested the binding of HA-SPIONs in 
excised human aortic valve samples. These results have illustrated the selective 
binding of HABP-SPIONs in particular to diseased samples. 
Our findings from these diverse experiments have demonstrated, overall, that the 
HA-targeted SPIONs described in this dissertation are suitable for further 
development as a contrast agent for the early detection of CAVD. MR studies 
indicated that, as expected, SPION functionalization with peptides does alter the 
MR signal of the final, HA targeted SPIONs, and that SPION binding to HA can be 
observed via MR, despite the limitations of this measurement. Cytotoxicity studies 
have confirmed that none of the functionalized SPIONs exhibited cytotoxic 
qualities. Transwell studies have shown that, while both HABP- and OPN-SPIONs 
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were able to pass through an endothelial barrier, only HABP-SPIONs exhibited 
significant subsequent binding to HA. Finally, in studies using excised human 
aortic valve samples, HABP-SPIONs showed selective binding to diseased 
samples. Together, these results suggest that HABP-SPIONs in particular have 
demonstrated the potential for success in their intended application, and merit 
further study as a potential MR contrast agent for early detection of CAVD.  
 
4.2 Materials and Methods 
A variety of experiments were performed using HABP-, OPN-, and PEG-SPIONs 
to determine whether these SPIONs are suitable for further development as a 
clinical contrast agent. These experiments evaluated the functionalized SPIONs 
in terms of their MR properties, cyto- and systemic toxicity, ability to pass through 




Materials previously discussed in Chapters 2 and 3 were obtained from the same 
sources described therein. Ticagel Bind-KX and FASTir Xanthan EC were 
generously donated by TIC Gums. The LIVE/DEAD assay kit was purchased from 
ThermoFisher Scientific (Waltham, MA). The 0.4µm pore, PE Transwell plates 
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were purchased from Corning, in addition to all cell culture flasks and plates 
(Corning, NY). Human aortic valve samples were obtained through the National 
Disease Research Interchange (NDRI, Philadelphia, PA).  
All statistical analysis and figure generation was performed in R, version 3.5.1.  
 
Preparation of Bound and Unbound Samples for MR Measurements 
The iron concentration in each solution was determined using a simple absorbance 
assay at 510nm, based on solutions containing known quantities of iron. Solutions 
at different concentrations (0, 5, 25, 50, 75, and 100 ppm) were prepared by 
dilution for MR. For evaluation of the relaxivity of functionalized SPIONs, these 
dilutions were performed in water. For evaluation of the relaxivities of bound vs. 
unbound SPIONs, the suspended HA solutions were created by mixing measured 
quantities of HA (Sigma, St. Louis, MO) with a gel-like mixture of 0.5% Ticagel 
Bind-KX and  0.1% FASTir Xanthan EC. For control (unbound) samples, the gel 
was created without the addition of HA. The solutions were stored in plastic 
cryogenic vials, and the amount of air in each vial was minimized to eliminate signal 
interference from the air-water interface. All vials were embedded into Styrofoam 




MR Equipment & Experiments 
Two MR experiments were performed for each set of samples. One experiment 
was designed to measure R2 and one was designed to measure R1. All 
experiments were performed on a 3 Tesla GE HDx clinical MR imager (GE, 
Milwaukee, WI) equipped with 40 mT/m gradients capable of 150 mT/m/sec slew 
rate and an 8-channel brain phased array receiver coil for signal reception.  
Because T2 measurements using this Hahn single echo spin echo sequence are 
sensitive to molecular diffusion, an experiment was performed to measure R2 using 
a three-dimensional multi-echo spin echo Carr-Purcell-Meiboom-Gill 
sequence.139–143 This sequence utilized non-selective radiofrequency pulses with 
composite refocusing (90x-180y-90x) as well as gradient crushers that alternated in 
polarity in every echo and that diminished in amplitude at every pair of echoes.144 
Sequence parameters were 1.5 sec TR, 16 echoes evenly spaced at 7.4 ms (first 
echo at 7.4 ms, last echo at 118.4 ms), 2 mm slice thickness, 13-15 cm FOV, 96 
(readout)  72 (phase)  38 (slice) matrix, 1 signal average, and 32.8 kHz 
bandwidth. SNR was typically >100 at the first echo, and reducing to no less than 
30 at the 4th echo for the highest agent concentration.  
R1 was measured using a two-dimensional single echo spin echo sequence but 
with a fixed echo time of 9 ms and independently repeated for 12 repetition times 
ranging from 100 ms to 9 sec (TRi=100, 250, 500, 750, 1000, 1366, 1750, 2500, 
4000, 5500, 7000, and 9000 ms). Other parameters were identical to the single 
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echo spin echo R2 experiment except that 4 signal averages were used for the 
shorter TRs in order to increase SNR, except for acquisitions with TR >2.5 sec for 
which only 1 signal average was used to maintain a reasonable scan time. With 
these parameters, SNR was between 10-30 for the three shortest TRs and >30 for 
the remaining TRs. 
 
MR Analysis 
Analysis of MR signal intensities to determine sample relaxation rates was 
performed using custom software developed in MATLAB (version R2013b, 
MathWorks Inc., Waltham MA). The software performed non-linear non-negative 
least squares fitting of signal intensity measurements across either the echo (for 
T2, T2*) or the repetition times (for T1), using idealized mono-exponential signal 
models. For T2 measurements, the signal model was 𝑠(𝑇𝐸𝑖) = 𝑠𝑇𝐸=0𝑒
−𝑇𝐸𝑖𝑅, where 
R the corresponding R2 relaxation rate. For T1 measurements, the signal model 
was 𝑠(𝑇𝑅𝑖) = 𝑠𝑇𝑅=∞(1 − 𝑒
−𝑇𝑅𝑖𝑅1) . In both models, the non-linear optimization 
routine solved for the spin density 𝑠𝑡={0,∞} and the corresponding relaxation rate. 
Signal intensities in each sample were measured using a custom software user 
interface (also developed in MATLAB). The software allowed all DICOM images 
corresponding to a single experiment to be loaded, and regions-of-interest (ROIs) 
to be placed in any source axial slice in the image volume of one acquisition. The 
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software then propagated the ROI to the corresponding slice and location in every 
acquisition in the experiment, thereby producing the average signal measurement 
for that ROI across the corresponding independent variable. ROIs were placed at 
the center of each vial for each solution concentration in at least 4 different axial 
slices covering the vial. The fitted relaxation times were recorded into Excel and 
averaged over the multitude of ROIs collected for each vial.  A least squares linear 
fit was finally used to calculate the agent relaxivity (r1, r2) as the slope of a straight 
line corresponding to the measured relaxation rates (R1, R2) vs. known iron 
concentration values of each vial. Standard error in the slope was also estimated 




A LIVE/DEAD assay was performed as recommended to assess cytotoxicity of 
functionalized SPIONs. Briefly, HUVECs were cultured as recommended on 
tissue-coated plastic. When cells were visibly confluent, enough SPION solution 
to reach a concentration of 100 parts per million (ppm) was diluted in standard cell 
media and added to the HUVECs. SPIONs were incubated with cells at 37°C for 2 
hours. Cells were rinsed with sterile PBS and stained as proscribed in the 
LIVE/DEAD kit protocol, with optimal concentrations of 1µM Calcein AM and 2µM 
Ethidium homodimer-1 having been previously determined in other HUVEC 
 
96 
samples. Cells were imaged on an Olympus IX81 microscope using appropriate 
fluorescent filters. Live and dead cells were quantified using ImageJ, and 
subsequent statistical analysis were performed in R.  
 
Hydroxyapatite Nucleation and Formation Studies 
Similarly to the protocols previously described, this protocol was adapted from 
work by de Bruyn et al.100 Two working solutions were prepared in advance (0.5M 
CaCl2 and 0.25M Na2HPO4). On the day that measurements were performed, 
these solutions were diluted in either DI water or 50% serum to 12mM CaCl2 and 
7.5mM Na2HPO4, respectively, and the pH of all solutions was adjusted to 7.4. 
These solutions were mixed in a 1:1 ratio. SPION samples or peptides were added 
such that the additional solution made up 1/10th the volume of the total solution, 
keeping concentrations of either SPIONs or peptides consistent across 
experiments. Mixed solutions were measured every 4 minutes for a total of 40 
minutes via DLS, as previously described. Control solutions were solutions where 
sodium phosphate buffer was added instead of either SPION samples or peptides. 
Sodium phosphate buffer was chosen as the control for these studies because 





Nanoparticle Endothelial Translocation Studies 
HUVECs were cultured at recommended conditions in T-75 flasks. When cells 
were 80% confluent, they were split into 0.4µm pore size, poly(ethylene) (PE) 
membrane transwells. Cells were cultured on the transwell membranes until they 
reached confluence, as determined by observation of the cell layer under a 
microscope and confirmed by TEER. TEER measurements were performed using 
an EVOM2 from World Precision Instruments. A schematic representing the 








Figure 4.2: Schematic of transwell experimental setup. Briefly, HUVECs are grown to a 
confluent monolayer on transwell membranes. The transwell membranes are loaded into 
centrifuge tubes, and solution containing nanoparticles is loaded into the top compartment 
(1). Some centrifuge tubes are pre-loaded with HA in the bottom compartment as labeled 
in the figure to measure binding to HA, while some do not so that translocation alone can 
be assessed. Following centrifugation, nanoparticles that have passed through the 
endothelial layer are in the bottom of the centrifuge tube (not shown). The entire solution 
in the bottom of the centrifuge tube is loaded into a filter centrifugation tube, so that any 
HA that may have been present can be filtered out. The solution that passes through this 
second filtration represents the nanoparticles that have passed through the endothelial 
membrane (2) and for tubes that contained HA, contains the SPIONs that remain unbound 
to the HA (3).   
 
For all nanoparticle translocation studies, all media was removed from the 
transwell inserts, and they were placed into 15mL conical tubes. For studies 
involving binding to HA, 10mg of HA was first deposited in the bottom of each 
conical tube via the addition of appropriate quantities of prepared, sterilized 0.5M 
CaCl2 and 0.25M Na2HPO4 solutions. These solutions were allowed to evaporate 
completely prior to translocation studies. Nanoparticles (HABP-, OPN-, or PEG-
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SPIONs) were loaded at a concentration of 200ppm in 50% serum into the 
transwell inserts, and the conical tubes were sealed by parafilm. The conical tubes 
were centrifuged at 2500rpm (1258 x g) for 10 minutes. Samples were agitated 
and allowed to incubate for 30 minutes after centrifugation. Liquid that passed 
through the transwell membrane was collected from the bottom of the conical tube, 
and loaded into 0.4µm Costar Spin-X centrifuge tubes. These samples were 
centrifuged at 3000rpm for 5 minutes to remove any HA and HA-bound SPIONs 
from the sample. To assess the concentration of nanoparticles remaining in 
solution subsequent to these tests, the absorbance of the filtered liquid was 
measured at 410nm, and compared to a concentration curve comprising known 
concentrations of HABP-, OPN-, or PEG-SPIONs in 50% serum solution. 
 
Binding Studies in Excised Human Aortic Valve Samples 
Excised valves from control samples (i.e. from donors who had not been 
diagnosed with AS) were obtained from the NDRI as formalin-fixed, paraffin-
embedded tissue. Portions of the tissue were deparaffinized in several washes of 
xylene and rehydrated in ethanol and water. Samples were blocked with 50% FBS 
before being incubated with SPIONs for 30 min. After exposure to SPIONs, 
samples were stained with Prussian blue stain for 35 min, and images of the 
samples were captured. After Prussian Blue staining, some samples were stained 
with silver nitrate using the Von Kossa method as well, as described.176 The Von 
 
100 
Kossa method relies on the reaction between silver ions and phosphate in the 
presence of acid, whereby the phosphate may be replaced by silver deposits, 
visualized as black/grey in color. Images of stained samples were collected via an 
iPhone camera and processed in ImageJ. 
Portions of non-diseased samples were sliced and mounted on slides. Slides were 
deparaffinized immediately prior to staining, as has been previously described177 
using a series of xylene and ethanol washes. For alizarin red staining, samples 
were incubated for 2 minutes with Alizarin Red solution, following which they were 
washed several times with acetone. For nanoparticle binding studies, samples 
were washed in DI water and incubated for 30 minutes with diluted nanoparticle 
solution in 50% FBS. The remaining nanoparticles were washed off with DI water, 
following which slides were incubated with Prussian Blue solution (a 1:1 mix of 5% 
potassium ferrocyanide and 5% HCl).  
Images of stained slides were collected via an Eclipse Ni-E microscope and 
assessed in ImageJ.  
 
4.3 Results 
Based on optimization results described in Chapter 3, all studies in this chapter 
were performed on 10nm core SPIONs with PEG brush chain lengths of 3.4k, 
PEGylated using method 2 (ligand exchange with citric acid, followed by the 
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addition of NH2-PEG via EDC/NHS chemistry) as these SPIONs showed the 
maximal MR signal in previous studies.  
 
MR Measurements 
As with the addition of PEG chains of different lengths, the addition of peptides to 
PEG has a marked impact on the MR signal, and in particular, on r2 (Figure 4.3). 
For CPMG-derived relaxivities, the MR signal for HABP-SPIONs is, on average, 
greater than that of either OPN- or PEG-SPIONs. However, the r1 trends are 
different, showing that PEG-SPIONs have a greater r1 signal than either HABP- or 
OPN-SPIONs. Importantly, differences between HABP- and OPN-SPIONS were 
observed. This indicates that, not only does the addition of a peptide impact the 
MR signal of the resulting particles, but also that the type and qualities of the 





Figure 4.3: MR results showing the measured signal differences between HABP-, OPN-, 
and PEG-SPIONs under non-binding conditions. Each bar represents the slope of a line 
over 5 different SPION samples at different concentrations, as calculated by using the 
least squares method to calculate the statistics for a straight line corresponding to the 
measured signal vs. known iron concentration values. The slope of this line corresponds 
to the relaxivity for the sample.  Error bars represent standard error in the calculation of 
this slope. Signal measured is (A) r1 (B) CPMG-derived r2. 
 
The MR properties of unbound vs. bound SPIONs were assessed to determine if 
there was a measurable signal difference between the two (Figure 4.4). Binding 
of SPIONs to HA is expected to yield increased relaxivities. Results generally 
indicated that bound HABP-SPIONs did exhibit higher relaxivities than unbound 
HABP-SPIONs, while OPN-SPIONs did not show a consistent trend. This confirms 
that HABP-SPIONs do bind to their HA target, and that this binding can be 
observed via MR. The error on these samples is notably higher than those in other 
samples tested in Chapter 3 and Figure 4.3, likely because these samples needed 
to be mixed into a gel-like solution to keep the HA suspended for the duration of 
the image scans. The lower magnitude of the relaxivities in comparison to other 
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samples tested in Chapter 3 and Figure 4.2 is also likely due to the gel-like nature 
of the suspension, which would naturally have a lower water content and lower 
water mobility than the samples that were previously tested. 
 
 
Figure 4.4: MR results showing the measured relaxivity differences between unbound 
(left) and bound (right) particles for both HABP-SPIONs (orange) and OPN-SPIONs 
(purple). Each bar represents the slope of a line over 5 different SPION samples at 
different concentrations, as calculated by using the least squares method to calculate the 
statistics for a straight line corresponding to the measured signal vs. known iron 
concentration values. The slope of this line corresponds to the relaxivity for the sample.  
Error bars represent standard error in the calculation of this slope. Signal measured is (A) 
r1 (B) CPMG-derived r2. (C) Raw T2 weighted image. 
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However, as discussed by Caravan, et al., with a longer correlation time as in for 
the bound nanoparticles, r2 is expected to increase more than r1; i.e. r2/r1 will 
increase from unbound particles to bound particles.178 While this is true for OPN-
SPIONs (unbound r2/r1 = 33.57 ± 6.67; bound r2/r1 = 56.73 ± 12.05), these results 
were inconclusive for HABP-SPIONs (unbound r2/r1 = 50.39 ± 29.44; bound r2/r1 = 
46.03 ± 8.95). The high error, as previously noted, may be due to incomplete 
mixing of the samples, as is also evidenced by the image of an MRI slice provided 
in Figure 4.4C. 
 
LIVE/DEAD Assay 
The specific cytotoxicity of functionalized SPIONS in HUVECs was examined via 
a LIVE/DEAD assay (Figure 4.5).62 HUVECs were chosen for these studies 
because SPIONs entering the body via injection are most likely to encounter 
endothelial cells. After incubation with various functionalized SPIONs, samples 
that had been incubated with HABP-, OPN-, and PEG-SPIONs did not show 





Hydroxyapatite Nucleation and Formation Studies 
The impact of functionalized SPIONs on HA nucleation and formation was 
assessed (Figure 4.6). Results in buffer solution with HABP and OPN peptides 
alone (unconjugated to SPIONs) indicated that the OPN peptide has an inhibitory 
effect on the nucleation and formation of HA nanocrystals (Figure 4.6A). There is 
no significant difference between the control sample and HABP peptide alone 
(p >0.05); however, there was a significant difference between the control sample 
and the OPN peptide (p < 0.05). This result was expected based on previous 
research which described similar effects of OPN. When HABP and OPN were 
conjugated onto SPIONs, however, this effect was not observed (Figure 4.6B). 
Instead, buffer solutions with either HABP- and OPN-SPIONs showed potentially 
more rapid nucleation and formation of HA nanocrystals, with significantly larger 
crystals observed at almost every timepoint except at 24 and 40 minutes (p < 0.05).  
Figure 4.5: Results from a LIVE-DEAD 
assay indicating that HABP-, OPN-, 
and PEG-SPIONs do not demonstrate 
significant (p < 0.05) toxicity to 
HUVECs after incubation. The 
incubation of HUVECs HABP-, OPN-, 
and PEG-SPIONs for 2 hours does not 
lead to increased cytotoxicity when 
compared to the control. For these 
studies, error bars are standard 




Figure 4.6: Examination of the impact of HABP- and OPN-SPIONs on HA nucleation and 
formation in vitro. HA nucleation and the formation of nanocrystals was measured over 40 
minutes via DLS, and the impacts of the presence of (A) HABP and OPN peptides alone 
in buffer, (B) HABP- and OPN-SPIONs in buffer, (C) HABP and OPN peptides alone in 
50% serum, and (D) HABP- and OPN-SPIONs in 50% serum were evaluated. 
 
However, neither of these trends were observed in samples containing 50% serum 
(Figure 4.6 C and D). In the presence of 50% serum, there were no observable or 
quantifiable differences in HA nucleation and formation in samples containing 
HABP and OPN peptides, or in samples containing HABP- and OPN-SPIONs, in 
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comparison to the control, where only sodium phosphate buffer has been added. 
Serum in general appears to prohibit HA nucleation and formation.    
 
Nanoparticle Endothelial Translocation Studies 
The ability of functionalized SPIONs to pass through an endothelial layer was 
assessed via the setup shown in Figure 4.7. Briefly, HUVECs are cultured on 
0.4µm PE transwell membranes until confluent. Confluence was confirmed by 
transepithelial electrical resistance measurements (TEER), which was calculated 
using the equation:   𝑇𝐸𝐸𝑅𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑑 = (Ω𝑐𝑒𝑙𝑙 𝑠ℎ𝑒𝑒𝑡 − Ω𝑡𝑟𝑎𝑛𝑠𝑤𝑒𝑙𝑙 )  ∙  𝑎𝑟𝑒𝑎 . These 
calculations yielded a TEER measurement of 18.4 ± 1.9 Ωcm2, which is in keeping 
with results from the literature indicating that confluence for HUVECs on transwell 
membranes is considered to correspond to a range of TEERs between 10-20 
Ωcm2.179–181  
For centrifugation through the epithelial layer and transwell membrane in the 
center step, calculations were performed to determine a centrifugation speed that 
would come close to, but not exceed, the pressure that would be experienced by 
particles under blood flow conditions. Those calculations are shown below (Figure 
4.7). It was determined from these calculations that 2500 rpm, or 1258 x g was an 




Figure 4.7: Comparison of forces generated by blood flow to those generated by 
centrifugation on the endothelial layer growing on a transwell membrane. The force 
generated by centrifugation approaches that of the pressure on the valve during diastole 
without exceeding it, meaning that this rate of centrifugation is appropriate for the 
experiments described.  
 
The absorbance of samples in the transwell setup is measured at several steps 
throughout the process to evaluate the concentration of nanoparticles at each step. 
Each step at which the absorbance is measured is indicated by a number in Figure 
4.2, and has a corresponding labeled bar in Figure 4.8A. To summarize, 
nanoparticle concentrations were measured upon initial placement of 200ppm of 
particle solution into the transwell apparatus (#1), and then after the second round 
of centrifugation both for samples not containing HA (#2), and for samples 
containing HA (#3).   A concentration curve for each type of nanoparticle tested 




Figure 4.8: (A) Results from transwell experiments depicted in Figure 4.4. Results indicate 
the concentration of SPIONs added into the transwell compartment (rightmost bar for each 
coating type), the concentration of SPIONs in the solution that has been centrifuged 
through the endothelial layer on the transwell membrane (middle bar), and the 
concentration of SPIONs remaining after binding to HA has been allowed to occur 
(rightmost bar). Statistical significance (p < 0.05) is indicated by *, error bars are standard 
deviation, and n=3.  (B) Example image of hemocytometer after loading with fluid 
centrifuged through the endothelial layer on a transwell membrane, indicating that there 
are no dead (or live) cells that have been forced through the transwell membrane.  
 
Results in Figure 4.8A indicated that both HABP- and OPN-SPIONs are able to 
pass through the endothelial barrier and the transwell membrane (#2, orange and 
purple bars). The concentration of HABP-SPIONs remaining in the solution that 
has passed through the endothelial barrier is significantly less than the starting 
concentration of 200ppm (p < 0.05); on average, 35.7% of HABP-SPIONs pass 
through during centrifugation. Likewise, the concentration of OPN-SPIONs 
remaining in the solution that has passed through the endothelial barrier is 
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significantly less than the starting concentration of 200ppm (p < 0.05); on average, 
46.7% of OPN-SPIONs pass through during centrifugation. The difference 
between the concentrations of the HABP- and OPN-SPIONs that passed through 
the endothelial barrier was not significant (p > 0.05). PEG-SPIONS, on the whole, 
appear unable to pass through the endothelial barrier (#2, blue bar).  
The ability of functionalized SPIONs to bind to HA after passing through the 
endothelial barrier was also assessed (#3). In samples where HA was loaded into 
the centrifuge tube, so that any material that passed through the endothelial barrier 
would be allowed to bind to the HA, the measured concentration of HABP-SPIONs 
in the final solution was significantly less than the concentration of samples with 
no HA in the bottom of the centrifuge tube (p < 0.05). The average concentration 
of SPIONs decreased from ~71.5 to ~0ppm. However, the concentrations of OPN-
SPIONs between these two samples did not significantly alter (p > 0.05), though 
the average concentration again decreased from ~93.5 to ~76.9ppm. There was 
no significant difference between these two sets of samples for PEG-SPIONs (p > 
0.05).  
The solution that passed through the endothelial barrier and transwell membrane 
was additionally assessed via hemocytometer to determine if any live or dead cells 
were passing through the membrane (Figure 4.8B). As expected, no evidence of 
live or dead whole cells was observed, indicating that, unlike nanoparticles, cells 
were not able to pass through the transwell membrane.  
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Binding Studies in Excised Human Aortic Valve Samples 
Human aortic valve samples were obtained from the NDRI as formalin-fixed, 
paraffin-embedded sections. These samples were obtained from deceased tissue 
donors, as well as donors who had the aortic valve removed as part of a SAVR 
procedure. Donors were all over 60 years of age, and were comprised of both men 
and women. Limited information was available for each individual donor, as tissues 
were de-identified in keeping with an exemption letter obtained from Boston 
University's Institutional Review Board.  
Stenotic tissue could not be sliced using a microtome. Therefore, to perform 
comparable studies on both diseased and non-diseased samples, tissue samples 
were cut into sections, and the sections were incubated with 50% FBS (to block 
non-specific binding) and functionalized SPIONs before washing and staining with 
Prussian Blue to visualize areas where SPIONs had deposited (Figure 4.9). 
Subsequent to Prussian Blue staining, samples were stained using the Von Kossa 
method to observe any colocation between the stains. Sections of normal tissue 
were also prepared similarly in order to observe any visible off-target binding. 
While microscopic calcium or HA deposits may be observed in non-diseased tissue, 




Figure 4.9: Selected images from experiments looking at binding of HABP-, OPN-, and 
PEG-SPIONs to both diseased valve samples and normal tissue. Nanoparticle binding is 
indicated by the blue color due to Prussian Blue staining for iron. Von Kossa staining for 
calcium is indicated by dark grey-black areas. All tissue samples were incubated with 
50% serum prior to the addition of nanoparticles. While all particles showed some 
degree of binding to diseased valve tissue, PEG-SPIONs also showed substantial off-
target binding to normal tissue.  
 
Results from these studies indicated that HABP-, OPN-, and PEG-SPIONs all 
show visible binding to diseased valve samples (see the blue/green color in the 
first column of Figure 4.9). This is perhaps unsurprising, given the results 
demonstrated in Chapter 2. It is worth restating that PEG-SPIONs showed 
substantial binding to cholesterol in the studies discussed in Chapter 2; diseased 
valve tissue would be expected to have cholesterol deposits in addition to HA 
deposits, so the binding of PEG-SPIONs to diseased valve tissue may be expected. 
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After incubation with nanoparticles and staining with Prussian Blue, samples were 
also stained using the Von Kossa method (see grey-black color in the second 
column Figure 4.9). The Von Kossa method was chosen for this application 
because there is no cross-reaction with iron. The colocalization of the Prussian 
Blue and Von Kossa stains, which would indicate that the SPIONs are binding to 
calcium-phosphate deposits in the diseased tissue, was observed primarily in 
HABP-SPIONs, where the blue color from the Prussian Blue stain was overlaid 
with a darker grey-black stain. OPN-SPIONs also showed some colocalization as 
well, but qualitatively, not as strongly as the HABP-SPIONs. PEG-SPIONs showed 
some colocalization, but also a significant amount of off-target binding, as 
evidenced by the large grey and black deposits in an area of the sample that 
exhibited no blue staining. PEG-SPIONs also showed visibly detectable binding to 
non-diseased samples, while OPN-SPIONs showed less off-target binding, and 
HABP-SPIONs did not show appreciable off-target binding.  
Similar experiments with Prussian Blue staining were repeated across 3 different 
samples, with 3 replicates for each sample tested. Results across all experiments 
were collected and scored on a scale from 1-5, with 1 meaning “No visible blue 
stain” and 5 meaning “Substantial blue deposits.” These results were all put into a 
heat map (Figure 4.11A), and averaged across runs for easier visualization 
(Figure 4.11B). These results confirmed observations from Figure 4.10 that, while 
HABP-, OPN-, and PEG-SPIONs all demonstrate some degree of binding to 
diseased samples, off target binding is observed strongly with PEG-SPIONs, 
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weakly with OPN-SPIONs, and to a very small degree with HABP-SPIONs. In 
addition, HABP-SPIONs bind more consistently to diseased samples than either 
OPN-SPIONs or PEG-SPIONs.  
 
 
Figure 4.10: Heat map representation of experiments testing binding of SPIONs to 
excised human aortic valve samples. Darker blue shading corresponds to more 
observed binding. (A) Representation of all results across all replicates, and (B) 
representation of results averaged across replicates for easier visualization. 
 
Because of these results, HABP-SPIONs alone were selected for further study 
using additional methods. With the remaining non-diseased samples, we were able 
to mount slices of tissue sections onto microscope slides. Although these non-
diseased samples did not show macroscopic evidence of calcium deposits, it is 
feasible or even likely that microscopic calcium deposits may be observed because 
the age of all donors was >60 years old. To test this, and to determine if these 
 
115 
microcalcifications could be detected by HABP-SPIONs, two consecutive tissue 
slices were mounted on a single slide, allowing separate stains to be performed 
on each slice. One slice was exposed to HABP-SPIONs and stained with Prussian 
blue; the other was stained with Alizarin red, which stains calcium deposits red. 
Alizarin red was chosen for these studies because the resulting red color was more 
readily isolated via a simple red light filter. Co-staining of a single slice was not 
useful in these studies because Alizarin red cross-reacts with iron. These slices 
were imaged with a color microscope, allowing separation of the color channels 
(i.e. isolation of the blue channel to isolate Prussian blue stain, isolation of the red 
channel to isolate Alizarin red stain). False-color images for ease of visualization 
are provided in Figure 4.11A and B, indicating a very similar stain pattern and, 






Several staining procedures were performed on remaining non-diseased tissue, 
and the quantity of red stain in Alizarin red-stained slices was compared with the 
quantity of blue stain in Prussian blue-stained slices for each pair of slices mounted 
on a single slide. Stain quantifications were performed using ImageJ. Results from 
this comparison are in Figure 4.11C. A linear regression was performed, indicating 
a significant positive trend and strong correlation, with R = 0.72 and p = 0.0016. 
Although these results are preliminary, this correlation provides good evidence that 
HABP-SPIONs may additionally be able to detect microcalcifications in early-stage 
CAVD. 
 
Figure 4.11: (A) Microscope image of 
non-diseased valve sample stained 
with Alizarin Red at magnification 4x. 
The red channel of the original image 
was isolated and false colored in 
ImageJ for ease of visualization. (B) 
Microscope image of non-diseased 
valve incubated with HABP-SPIONs 
and stained with Prussian blue at 
magnification 4x. The blue channel of 
the original image was isolated and 
false colored in ImageJ for ease of 
visualization. (C) Quantification of red 
intensity vs. blue intensity for paired 
valve slices stained with Alizarin Red 
(y axis) vs. Prussian blue (x axis) to 
visualize correlation between red and 
blue stain in paired samples. A simple 
linear regression was performed 
(black line), and the grey shading 
indicates the 95% confidence 




Understanding the medically-relevant properties of HA-SPIONs is key to their 
application as a contrast agent for early CAVD detection. To this end, the medical 
relevance of functionalized SPIONs was assessed on several fronts, including the 
MR contrast they generate, their cytotoxicity to endothelial cells, their interaction 
with and impact on HA nucleation and formation, their ability to pass through an 
endothelial layer and bind to HA subsequently, and their ability to detect HA 
deposits in excised human aortic valve samples.  
Previous results discussed in Chapter 3 indicated that relaxivities for SPIONs could 
be optimized by adjusting the chemical and physical properties of the SPIONs. 
However, these results did not account for differences in relaxivity caused by the 
addition of peptides. Figure 4.3 indicates that the addition of peptides does further 
impact the measured relaxivities, and that this impact actually depends on the 
nature of the peptide itself. The differences observed between the relaxivities of 
HABP- and OPN-SPIONs could be due to several factors, including the differences 
in peptide properties listed in Table 2.2. Notably, the number of hydrophobic 
residues is much higher for HABP (6 residues) than for OPN (1 residue). As 
observed with differences between relaxivity with different methods of PEGylation 
in Chapter 3, the hydrophobicity or hydrophilicity of groups close to the SPION 
core may make a substantial difference in the MR properties of the resulting 
SPIONs. However, unlike in Chapter 3, where hydrophobic groups close to the 
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core resulted in lower MR signal, here we observe that a hydrophobic peptide 
attached to the PEG actually increases r1 and r2. It is hypothesized that, while a 
hydrophobic moiety closest to the core prevents water from approaching close to 
the core, a somewhat hydrophobic moiety partially surrounding the hydrophilic 
moiety closest to the core may actually serve to trap water molecules in close 
proximity to the core. Alternatively, or additionally, it is possible that some degree 
of aggregation of HABP-SPIONs plays a role in their increased relaxivity. As 
discussed in Chapter 3, HABP-SPIONs fabricated to have ~100 peptides/SPION 
aggregated immediately and dropped out of solution; perhaps a smaller amount or 
degree of aggregation is occurring in all HABP-SPIONs. Further studies would be 
needed to determine the precise cause of the signal enhancement observed in 
HABP-SPIONs. 
The impact of binding to HA on relaxivities was also assessed (Figure 4.4). In 
general, previous research has demonstrated that bound particles exhibit 
increased relaxivities. Bound particles move through water more slowly, thus 
giving water molecules more time on average close to the core and increasing the 
apparent relaxivity. As expected, bound HABP-SPIONs did demonstrate increased 
relaxivity in comparison to unbound particles, thus confirming particle binding via 
an additional method orthogonal to those used in Chapter 2. However, OPN-
SPIONs did not. On the other hand, OPN-SPIONs exhibited the expected increase 
in r2/r1, while results for HABP-SPIONs were inconclusive. It is hypothesized that 
this inconsistency may have been due to the incomplete sample mixing visible via 
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MRI and caused by the gel-like nature of the HA suspension. Although the method 
of mixing used in these experiments showed the best results of any method 
attempted thus far, samples still failed to mix completely. In the future, it may be 
beneficial to perform imaging on bound SPIONs that are not suspended in liquid, 
although it may be difficult to obtain relaxivities from these kinds of experiments.  
The gel-like matrix necessary to suspend HA for the necessary length of time to 
perform MR measurements severely impacted the resulting relaxivities, and 
potentially the magnitude of the error. It is also hypothesized that the error may be 
high because not all nanoparticles were bound to HA upon testing; as HA was 
added to the gel prior to the addition of particles in order to facilitate mixing of the 
gel and consistent suspension of the HA, it is possible that not all particles added 
subsequently were bound to HA (i.e. incomplete mixing between HA and SPIONs 
may have been an issue). However, studies performed where all of the particles 
were bound to HA prior to the addition of the HA-particle complexes to the gel (data 
not shown) showed even higher error and visible failure to mix, even after 24 hours 
of vigorous agitation. Thus, even though particle binding may have been 
incomplete, the methods used to produce the data shown in Figure 4.4 are 
preferable. However, because incomplete binding may have been an issue, we 
cannot say quantitatively that these relaxivities represent those that could be 
observed under 100% bound conditions. Instead, we conclude that examining the 
qualitative trends in the data (i.e. that bound HABP-SPION particles generally 
exhibited higher MR signal than unbound HABP-SPION particles) indicates 
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successful binding of both HABP-SPIONs to HA.  
Cytotoxicity studies performed confirm what has been previously shown in the 
literature: that polymer-coated and functionalized SPIONs are not cytotoxic, and 
are generally safe for biological use at physiologically-relevant concentrations 
(Figure 4.5).98,115,182 Although this was demonstrably true in HUVECs after 2 hours 
of incubation, the effects of repeated exposure were not assessed in this system. 
Additionally, broader effects of exposure, as previously described by Singh et al., 
have not yet been assessed for these particular SPIONs.165 Therefore, future 
experiments will need to address issues of systemic toxicity and repeated 
exposure.  
Because functionalized SPIONs bind to HA, as demonstrated both in Chapter 2 
and Figure 4.4, it is possible that they have an impact on HA nucleation and 
formation. This is particularly true because previous research has demonstrated 
that the OPN peptide alone, as discussed previously, can disrupt HA crystal 
formation. Although in calcific deposits found in CAVD this disruption may be an 
advantage, the functionalized SPIONs are expected to show some degree of off-
target binding to bone throughout the body, where the potential disruption of HA 
crystal formation and deposition may have negative physiological impacts. Bone 
mineral in the body is consistently undergoing resorption and redeposition 
processes, and interfering with these processes is thought to play a role in 
diseases such as osteoporosis.73,166  
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However, while the OPN peptide alone did, as expected, slow HA nanocrystal 
nucleation and formation, both HABP- and OPN-conjugated SPIONs actually 
seemed to increase the rate of HA nanocrystal nucleation and formation in buffer 
(Figure 4.6). This could also lead to a variety of negative physiological impacts. 
Fortunately, this effect was limited to buffer-only solution; upon the addition of 50% 
serum, it was observed that HABP and OPN peptide alone, in addition to HABP- 
and OPN-SPIONs, showed no difference from the control in terms of HA 
nanocrystal nucleation and formation (Figure 4.6). This indicates that addition of 
particles may not have theranostic applications, but also that they are safe for 
systemic administration. 
Evaluating the ability of SPIONs to pass through an endothelial barrier and still 
bind to HA is a particularly important set of experiments, given that the small HA 
deposits present in early CAVD are largely present underneath the epithelium of 
the aortic valve. Although it is possible to use a transwell setup to examine the 
diffusion of particles through an endothelial layer, as has been described in many 
previous studies, in these studies we wanted to recapitulate, to whatever degree 
possible, the forces that will act on the particles as they are under the pressure of 
blood flow. To this end, a centrifuge speed was chosen as previously described to 
approach, but not exceed the pressure that would be experienced by particles in 
the bloodstream, especially given that it is likely that the endothelial barrier in vivo 
will exhibit higher integrity than the in vitro endothelial layer on the transwell 
membrane. Although TEER measurements are not typically performed in vivo, 
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estimates of TEER values up to or over 1000 Ωcm2 have been reported from 
various cell types in different barrier models.183–185 However, it has also been well-
established that the presence of inflammation or inflammatory cytokines, such as 
those present in CAVD, does decrease the barrier function of endothelial 
cells.183,186,187 Thus, although the transwell apparatus and the HUVECs used for 
these studies may not recapitulate precisely the barrier function of valvular 
endothelial cells, they may serve as an adequate stand-in for the evaluation of 
endothelial function under the inflammatory conditions present in CAVD and AS.  
Results from these transwell experiments indicated that HABP- and OPN-SPIONs 
both successfully passed through the endothelial layer and transwell membrane 
upon centrifugation (Figure 4.8). As expected, not all of the particles passed 
through. However, the rates of passage were comparable for both HABP- and 
OPN-SPIONs, and were far greater than the rates of passive diffusion of 
nanoparticles through an endothelial layer as described by Kim et al.168 This is to 
be expected, given that these particles were under additional direct pressure to 
pass through the barrier, as would be physiologically accurate for particles passing 
through the endothelial barrier of an aortic valve under blood flow.  
However, PEGylated SPIONs without the addition of peptide were unable to pass 
through (Figure 4.8). It is unknown whether the PEGylated particles without 
peptides did not pass through because of interactions with the endothelial layer 
itself, or because of interactions with the transwell membrane.  It may be due, 
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again, to the somewhat hydrophobic nature of the PEGylated SPIONs, and the 
potential for their interaction with the transwell membrane itself – in much the same 
way that the PEGylated particles alone showed high levels of interaction with 
cholesterol. The material of the transwell membranes, polyethylene, is also 
somewhat hydrophobic. Although the surface of the transwell membranes is 
treated for tissue culture, the pores themselves may not be fully treated, and 
PEGylated particles traveling through the pores may get stuck. If this is the case, 
repeating similar experiments with whole excised human valve samples may show 
that PEGylated particles are able to pass through the endothelial layer; future work 
will be necessary to determine whether this is true.  
For studies involving binding of particles to HA subsequent to passage through the 
endothelial layer, HA was fabricated by drying a borderline saturated calcium 
phosphate solution. This method was chosen, rather than using powdered HA that 
can be purchased, because it may more accurately recapitulate the mixture 
between crystalline HA and amorphous, insoluble calcium phosphate that is 
present in bone mineral in vivo. HABP-SPIONs exhibited significant binding (p < 
0.05) to ~10mg of HA produced by this method after passing through the 
endothelial barrier, while OPN-SPIONs did not exhibit significant binding (p > 0.05) 
(Figure 4.8). This is somewhat in keeping with the results observed in Chapter 2, 
Figure 2.9, where HABP-SPIONs, on average, bind in higher quantities to HA than 
OPN-SPIONs after exposure to serum. It is possible that OPN-SPIONs also exhibit 
binding, but more replicate experiments would need to be performed to reach 
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significant differences. However, based on these results, it appears that HABP-
SPIONs may be more promising for applications in CAVD detection, as they are 
undoubtedly able to pass through the endothelial layer and bind to HA after 
passage. 
Studies comparing HA-targeted and non-targeted binding of SPIONs to diseased 
and non-diseased aortic valve samples yielded exciting results. Overall, through 
all samples tested, it appeared that HABP-, OPN-, and PEG-SPIONs 
demonstrated binding to diseased samples in significant enough quantities that 
staining with Prussian Blue yielded visible results. Generally speaking, HABP-
SPIONs demonstrated higher levels of binding than either OPN-SPIONs or PEG-
SPIONs, as well as better colocalization with calcium deposits as visualized by 
Von Kossa staining. Additionally, PEG-SPIONs show very substantial, 
macroscopically-visible binding to non-diseased samples, while OPN-SPIONs 
showed only a low level of binding to these samples, and HABP-SPIONs showed 
very little, if any, visible off-target binding. Preliminary assessment of samples that 
did not show macroscopic disease indicated that HABP-SPIONs may additionally 
bind to microcalcifications, although further studies will need to be performed on 
additional, intact human aortic valve samples to ascertain this observation. Taken 
together, these results confirm what other previous studies also suggested: that 
HABP-SPIONs are suitably selective in binding to diseased human tissue to act as 
targeted contrast agents in detection of CAVD.  
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Chapter 5: Conclusions and Further Studies  
In this dissertation, we describe the development, optimization, and testing of a 
hydroxyapatite-targeted SPION that can be used for the early detection of CAVD.  
In Chapter 2, we fabricated and characterized two different HA-targeted SPIONs 
using two distinct peptides (HABP and OPN). We evaluated the success of 
fabrication using DLS, zeta potential measurements, and the BCA assay to confirm 
peptide attachment. We characterized the in vitro binding properties of the SPIONs 
in the presence of both sodium phosphate buffer and 50% FBS. We then 
performed several studies to better understand the protein corona of HABP-, OPN-, 
and PEG-SPIONs, including studies to quantify the amount of protein in the hard 
vs. soft corona after various incubation times with serum. Ultimately, results 
demonstrated that, although all produced SPIONs immediately associated with 
serum proteins, the vast majority of protein interactions were both weak and non-
specific. It is hypothesized that this, in addition to the charge-based nature of the 
peptide interaction with HA, allows for specific binding to occur to HA even in the 
presence of 50% FBS. 
Studies to identify which specific proteins are present in the soft and hard corona 
of the various SPIONs were not performed as a part of this dissertation, but this 
could be an interesting direction to explore in the future. Techniques such as mass 
spectrometry and X-ray powder diffraction could readily be used to assess the 
makeup of the hard and soft protein coronas, which may give some insight into the 
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predicted behavior of various SPIONs in vivo. Similar experiments with SPIONs as 
well as other types of nanoparticles have been described in the literature;85,88,121 it 
may be useful in the future to compare the types of proteins shown to interact with 
those particles with the types of proteins that interact with HABP-, OPN-, or PEG-
SPIONs.  
In addition, observing different components of the protein corona in different 
matrices or under different conditions could provide some useful insights about the 
nature of the protein corona in general, and the nature of the SPION protein corona 
in particular. Previous studies, such as those by Lundqvist et al. have examined 
the different protein coronas that result from exposing nanoparticles to different 
matrices, such as FBS, human serum, and whole blood.188 These studies found 
that the protein corona of a given nanoparticle showed notable variation when the 
nanoparticles were placed in different matrices, particularly in human whole blood. 
Similar studies with HABP-, OPN-, and PEG-SPIONS could examine whether 
some of the proteins that are bound to SPIONs in whole blood are part of either 
the coagulation cascade or the complement system. The presence of these 
proteins in the corona might indicate that SPIONs may precipitate an immune 
reaction. Such results from these studies could provide important pre-clinical 
information in the further development of SPIONs as a clinical MR contrast agent.  
Another aspect of the SPION protein corona that could be examined is impact of 
flow conditions on the formation and make-up of the protein corona of these 
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SPIONs. Previous studies such as those from Palchetti et al. have indicated that 
the proteins that comprise the protein corona may be different under flow 
conditions.123 Since SPIONs will be under flow in vivo, these experiments could 
provide valuable insight into particle behavior, interactions, and the potential for an 
immune system response in vivo.  
In addition to studies to further examine the protein corona around HABP-, OPN-, 
and PEG-SPIONs, it may be useful or interesting to examine other peptides and 
potentially other disease targets. Hydroxyapatite was chosen as a favorable target 
based on several criteria discussed earlier; however, other potential disease 
targets were considered, such as markers of endothelial disruption, lipoprotein 
deposition, and masts cells or macrophages. Additionally, fabricating 
nanoparticles that can bind to e.g. endothelial disruption or macrophages may 
have implications for a range of diseases beyond CAVD, such as atherosclerosis 
and various forms of cancer.189–191 Ultimately, although targeting HA has several 
advantages, it may be worthwhile to evaluate SPIONs conjugated to peptides that 
specifically bind to these targets using a similar range of experiments to those 
described in Chapter 2.  
In Chapter 3, we explored optimization parameters of SPIONs in terms of both 
binding to HA as well as MR signal. We determined that altering the number or 
ratio of peptides per SPION did not have a substantial impact on SPION binding 
to HA within a range of reasonable peptide quantities. Although this may have 
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implications for cost efficiency of nanoparticle production in the future, this type of 
modification appears to be of less importance to particle functionality. 
PEGylation method, PEG chain length, and SPION core size all showed impacts 
on SPION MR relaxivities in solution. While the impact of PEG chain length 
depended on the PEGylation method, the effect of SPION core size was more 
consistent, showing that SPIONs with a larger core size generally have higher r2 
relaxivities. This is in keeping with what has been shown by LaConte et al.192 The 
effect of PEGylation method was perhaps the most influential factor, with NH2-
PEGylation showing, overall, higher relaxivities than either PO-PEGylation or 
DSPE-PEGylation. It is hypothesized that this is due to the hydrophilicity of the CA-
SPION core produced for NH2-PEGylation, as compared to the more hydrophobic 
core produced using the other two PEGylation methods. Ultimately, these studies 
helped to determine that the optimal particle would have a 10nm core, 
functionalized with either 3.4kDa or 5kDa PEG chains using the NH2-PEGylation 
method for optimal MR signal.  
Because relatively little work has been done on MR signal optimization across 
physiochemically distinct SPIONs, there are many future directions that could be 
explored in these studies. For example, it would be interesting to observe how 
different media may impact the MR signals or trends therein. The motility of water 
around the particles may alter in serum or whole blood as compared to the sodium 
phosphate buffer used in these studies, which would in turn impact the MR signal. 
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These trends have largely not been explored in the literature, and could yield 
interesting results that may provide insight about particle behavior and movement 
in different media. Although it would be challenging if not impossible to perform 
similar studies looking at MR signal of particles bound to HA in different media due 
to the gel-like material needed to successfully suspend HA for the duration of the 
scan, non-binding studies may still hold useful insights, particularly about potential 
particle behavior in a more clinically relevant environment.  
Additionally, although a relatively narrow range of PEG chain lengths were 
selected for the studies described in Chapter 3, future studies could examine a 
wider range of PEG chain lengths, such as those < 1000 kDa or > 10,000 kDa. A 
report by LaConte et al. indicated that the response of R2 to differences in PEG 
chain length for lengths <1000 kDa differed substantially from the impact for 
those  >1000 kDa.192 This is a population that was not explored in these studies, 
and wider variation in PEG chain length could be well worth assessing in the future. 
Other nanoparticle design parameters could be varied as well, such as the use of 
different PEG chain lengths on a single particle.  
Finally, although two SPION core sizes were assessed, it was observed that 
neither produced significant positive (T1) contrast. However, some studies have 
shown that certain SPIONs can be used as T1 contrast agents, and this is an active 
area of research in the field.149,193,194 T1 contrast agents are often preferred 
clinically to T2 contrast agents because the brightness of the contrast agent is 
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more easily detected and has better resolution.195 However, much like other 
SPIONs, studies have not been performed to optimize the T1 signal of such 
ultrasmall SPIONs. If smaller SPIONs such as those described by Wei et al. could 
be produced, it would be worthwhile to perform further studies to assess the 
behavior and MR signal of these SPIONs while varying PEG chain length and 
PEGylation method as well.  
In Chapter 4, we assessed the medically-relevant properties of targeted SPIONs. 
First, we measured the MR signal of the fully functionalized SPIONs, before 
examining the MR signal of bound vs. unbound targeted SPIONs to ensure that 
binding was occurring. Results from these studies indicated that fully-
functionalized SPIONs show relaxivities within the expected ranges, and that there 
is a measurable difference in signal as expected between bound and unbound 
SPIONs. Cytotoxicity studies confirmed that functionalized SPIONs do not 
demonstrate cytotoxic effects upon incubation with HUVECs, and so SPIONs are 
expected to be safe for medical use. The potential for some systemic effects was 
evaluated by examining the impact of both peptides and peptide-functionalized 
SPIONs on the nucleation and formation of HA crystals. Although peptides and 
SPIONs in buffer were both observed to have effects on HA nucleation and 
formation, in the presence of serum, neither peptides nor peptide-functionalized 
SPIONs exhibited behaviors different from a control sample. Thus, there should 
not be concern about the systemic impact of HA-targeted SPIONs on bone 
homeostasis. Studies performed using a unique, customized transwell setup 
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confirmed the ability of targeted SPIONs to pass through a model endothelial 
barrier, and HABP-SPIONs demonstrated significant binding to HA subsequently. 
Finally, the binding of SPIONs to excised human valve samples was evaluated. 
Although HABP-, OPN-, and PEG-SPIONs all showed visible binding to diseased 
samples, PEG-SPIONs also showed substantial binding to non-diseased samples, 
while OPN-SPIONs were more selective, and HABP-SPIONs showed little to no 
off-target binding to non-diseased samples. Taken together, these results indicate 
that HABP-SPIONs show great promise as potential contrast agents for the 
detection of calcification in human aortic valves. 
There are a multitude of studies that could be performed in the further development 
of HABP-SPIONs as potential contrast agents in the early detection of CAVD. One 
potentially useful set of studies would be broader evaluation of nanoparticle 
cytotoxicity. Although SPIONs are not expected to be immediately cytotoxic, the 
long-term effects of incubation with SPIONs have not been as thoroughly assessed. 
A review of several studies by Singh, et. al has indicated that some SPIONs at 
some doses can cause cytotoxicity via a variety of pathways, including impaired 
mitochondrial function, generation of reactive oxygen species, and DNA 
damage.165 These effects largely appear to be dependent on the dosage, surface 
modifications, and exposure time of the administered SPIONs, in addition to the 
cell type used in evaluation.196 A more comprehensive examination of HA-targeted 
SPION toxicity would include assessments of mitochondrial function as well as 
 
132 
measurements of genotoxicity using the comet assay. It may also be beneficial to 
test a larger variety of incubation times with HA-SPIONs. 
A crucial set of studies to perform in the future will be the assessment of HABP-
SPION binding to whole, rather than sectioned, aortic valve samples. Studies in 
this dissertation were limited by the availability of human samples. While the 
studies in this dissertation suggest that SPIONs will be able to pass through the 
endothelial membrane coating early calcium deposits and bind to the HA 
underneath, this will need to be confirmed in follow-up studies. These studies could 
also be performed on valves from patients at varying disease stages, thus allowing 
us to examine whether SPION binding occurs proportionally to calcium deposition 
in the valves. It would also be beneficial for these studies to image the excised 
valves using an MR scanner. Such results would help to confirm that HA-targeted 
SPIONs can bind to HA in whole valve samples in sufficient quantities to generate 
a measurable MR signal. These studies could additionally serve to evaluate 
various approaches for delivery of HA-SPIONs as a contrast agent by embedding 
the excised aortic valve samples in a physiologic flow loop of the aorta filled with 
a circulating physiologic nutrient solution.  
Further preclinical studies would need to examine nanoparticle safety and efficacy 
in an animal model. Although, as previously discussed, there is not an optimal 
animal model for CAVD, animal studies could provide critical information in terms 
of safety, dosing, and timing of the MR scan subsequent to nanoparticle 
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administration. Because HA deposition is a disease feature in atherosclerosis as 
well as aortic stenosis, it may be possible to use an animal model of atherosclerotic 
disease for these studies.  
Finally, it is possible that the nanoparticles described in this dissertation could have 
uses for other applications or diseases. Hydroxyapatite formation and calcification 
is a feature of a wide variety of diseases, both cardiovascular and otherwise (e.g. 
chronic kidney disease). With respect to cardiovascular diseases, hydroxyapatite 
plays a role in diseases such as atherosclerosis, where calcium deposits in 
coronary arteries can indicate the presence of a plaque.60,197,198 Hydroxapatite is 
also found in calciphylaxis, which is characterized by arteriolar calcification of the 
media.199–201 In non-cardiovascular diseases, hydroxyapatite may be found in 
vascular calcifications present in chronic kidney disease as well.202,203 The ability 
to detect hydroxyapatite via MRI could potentially have benefits for these diseases 
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